

	Family Name (Last Name)	Lee
	Given Name (First Name)	Jih-Chin
	Country	Taiwan
	Official Title	Professor and Director
	Position / Department	Otolaryngology Head and Neck Surgery
	Institute	Tri-Service General Hospital
	E-mail	doc30450@gmail.com
Education Background	1989-1996 M.D .National Defense Medical Center, Taiwan 2012-2016 Ph. D. College of Biological Science and Technology, NCTU, Taiwan	
Field of Research	Head and neck cancers Thyroid and parathyroid surgery	
Publications (the latest 5 articles)	<p>Ovatodiolide suppresses oral carcinogenesis and stemness by down-regulating exosomal miR-21/PI3K cargo and preventing oncogenic transformation of normal gingival fibroblast. Cancers 2020 IF:6.162, 31/230=13.48%</p> <p>An Integrated Genomic Strategy to Identify CHRNA4 as a Diagnostic/Prognostic Biomarker for Targeted Therapy in Head and Neck Cancer. Cancers 2020 IF:6.162, 31/230=13.48%</p> <p>Pharyngeal reconstruction using a U-shaped pectoralis major myocutaneous flap: an effective technique that should not be forgotten. Eur Arch Otorhinolaryngol 2019 Sep 20 IF:1.75, 19/42=45.24%</p> <p>Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. Head Neck. 2019 IF:2.48, 10/42=23.8%</p> <p>Predictive factors of increased surgical drain output after thyroid lobectomy: a retrospective study. Gland Surg 2019 IF:1.922, 97/203=47.78% (</p>	



張家崙 醫師

- 助理教授, [血液腫瘤科](#)
- 主治醫師, [臺北市立萬芳醫院](#)
- 成員, [臺北醫學大學細胞治療與再生醫學研究中心](#)
- 電子郵件 richardch9@tmu.edu.tw

個人檔案

學歷

- 2000-2007 國立成功大學醫學系學士

經歷

- 臺北市立萬芳醫院內科部血管腫瘤科主任
- 臺北市立萬芳醫院血管腫瘤科主治醫師
- 2018.06- 臺北醫學大學醫學系內科學科助理教授
- 2010.08-2012.07 林口長庚醫院總醫師
- 2007.08-2010.07 林口長庚醫院住院醫師

研究成果

2023

[Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants](#)

Shao, Y. Y., Ho, C. L., Chang, C. S., [Chang, C. L.](#), Lee, J. K., Lin, H. J., Hsiao, H. H., Chao, T. C., Lin, C. Y. & Liaw, C. C., 3 月 2023, 於: [Acta Cardiologica Sinica](#). 39, 2, p. 242-253 12 p.

[Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study](#)

Wen, M. J., [Hsu, H. L.](#), [Chang, C. L.](#), Wang, J. H., [Kuo, C. N.](#), Hsin, Y. C. & [Chang, E. H.](#), 5 月 2023, 於: [PLoS ONE](#). 18, 5 MAY, e0286333.

2022

[Adjuvant Radiotherapy Is Associated with an Increase in the Survival of Old \(Aged over 80 Years\) and Very Old \(Aged over 90 Years\) Women with Breast Cancer Receiving Breast-](#)

Conserving Surgery

Huang, C. C., Chang, C. L., Sun, M., Chiang, M. F., Sum, S. Y., Zhang, J. & Wu, S. Y., 2 月 2022, 於: [Journal of Personalized Medicine](#). 12, 2, 287.

Anesthesia With Propofol Sedation Reduces Locoregional Recurrence in Patients With Breast Cancer Receiving Total Mastectomy Compared With Non-Propofol Anesthesia

Zhang, J., Chang, C. L., Lu, C. Y., Chen, H. M. & Wu, S. Y., 3 月 3 2022, 於: [Frontiers in Oncology](#). 12, 708632.

An updated systematic review and network meta-analysis comparing open, laparoscopic and robotic-assisted sacrocolpopexy for managing pelvic organ prolapse

Chang, C. L., Chen, C. H., Yang, S. S. D. & Chang, S. J., 10 月 2022, 於: [Journal of Robotic Surgery](#). 16, 5, p. 1037-1045 9 p.

A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology

Ho, C-L., Chao, T-Y., Chang, C. L., Lin, H. Y., Yang, F., Wang, Q. & Zhu, J., 2022, 於: [Journal of Clinical Oncology](#). 40, 16_suppl, p. e14560-e14560

Association between long-term opioid use and cancer risk in patients with chronic pain: a propensity score-matched cohort study

Sun, M., Lin, J. A., Chang, C. L., Wu, S. Y. & Zhang, J., 2022, (接受/付印) 於: [British Journal of Anaesthesia](#). 129, 1, p. 84-91 8 p.

Comparing the outcomes and effectiveness of robotic-assisted sacrocolpopexy and laparoscopic sacrocolpopexy in the treatment of pelvic organ prolapse

Chang, C. L., Chen, C. H. & Chang, S. J., 2 月 2022, 於: [International Urogynecology Journal](#). 33, 2, p. 297-308 12 p.

Effect of opioids on cancer survival in patients with chronic pain: a propensity score-matched population-based cohort study

Sun, M., Chang, C. L., Lu, C. Y., Zhang, J. & Wu, S. Y., 4 月 2022, 於: [British Journal of Anaesthesia](#). 128, 4, p. 708-717 10 p.

Primary appendiceal diffuse large B-cell lymphoma initially presenting as acute appendicitis: A case report

Liu, K. Y., Wu, S. M., Chen, W. Y. & Chang, C. L., 4 月 2022, 於: [International Journal of Surgery Case Reports](#). 93, 106933.

Sarcopenia as an Independent Risk Factor for Specific Cancers: A Propensity Score-Matched Asian Population-Based Cohort Study

Sun, M. Y., Chang, C. L., Lu, C. Y., Wu, S. Y. & Zhang, J. Q., 5 月 1 2022, 於: [Nutrients](#). 14, 9, 1910.

Selenium Yeast and Fish Oil Combination Diminishes Cancer Stem Cell Traits and Reverses Cisplatin Resistance in A549 Sphere Cells

Lai, I. C., Liao, C. H., [Hu, M. H.](#), [Chang, C. L.](#), Lai, G. M., [Chiou, T. J.](#), Hsia, S., Tsai, W. L., Lin, Y. Y., Chuang, S. E., [Whang-Peng, J.](#), Chen, H. Y. & Yao, C. J., 8 月 2022, 於: [Nutrients](#). 14, 15, 3232.

Survival Impact of Long-Term Tramadol Use on Breast Cancer for Patients with Chronic Pain: A Propensity Score-Matched Population-Based Cohort Study

Sun, M., [Chang, C. L.](#), Lu, C. Y., Wu, S. Y. & Zhang, J., 3 月 2022, 於: [Journal of Personalized Medicine](#). 12, 3, 384.

Curriculum Vitae

Name :

Tien-Hua Chen

Date of Birth :

1986-12-28

Business Address :

No.201, Sec. 2, Shipai Rd., Beitou District, Taipei City, Taiwan 11217, R.O.C

Professional Experience :

2021 Attending physician, Division of medical oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2018 Fellow, Division of medical oncology, Department of oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2015 Resident, Department of internal medicine, National Taiwan University Hospital Taipei, Taiwan (R.O.C)

2014 Resident, Post-Graduate Year Training, National Taiwan University Hospital Taipei, Taiwan (R.O.C)

Education and medical Training :

<Education>

2012, Bachelor of Medicine, National Taiwan University, Taiwan

<Medical training>

2018-now Fellow in Division of medical oncology, Department of oncology, Taipei Veterans General Hospital, Taipei, Taiwan (R.O.C)

2015-2018 Residency in Department of internal medicine, National Taiwan University Hospital Taipei, Taiwan (R.O.C)

2014-2015 Post-Graduate Year Training in National Taiwan University Hospital Taipei, Taiwan (R.O.C)

Board Certification :

Board of the Internal Medicine

The Board of Medical Oncology of Taiwan Oncology Society

Memberships :

The Society of Internal Medicine

Taiwan Oncology Society

Publications:

1. Chen, T-H, Chang, P-H, Yang, M-H. Novel immune-modulating drugs for advanced head and neck cancer. *Head & Neck*. 2019; 41: 46– 56.
2. Chen TH, Chen WS, Jiang JK et al. Effect of Primary Tumor Location on Postmetastasectomy Survival in Patients with Colorectal Cancer Liver Metastasis. *J Gastrointest Surg*. 2021 Mar;25(3):650-661.
3. Chen, T-H, Chang, P-H, Yang, M-H. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pre-treated recurrent and metastatic head and neck cancer. *J Chin Med Assoc*. 2021 Apr 1;84(4):361-367.
4. Tien- Hua Chen, Giun- Yi Hung, Chueh- Chuan Yen. Chemotherapy for osteosarcoma: Literature review and experience of Taipei veterans general hospital. *J Cancer Res Pract* 2021;8:9-12.
5. Lai CL, Chen TH, Chang PM, Tai SK, Chu PY, Yang MH. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors. *J Chin Med Assoc*. 2022 May 2.

Funding:

1. Taipei Veterans General Hospital (V111A-006), 2022
2. Yen Tjing Ling Medical Foundation (CI-111-14), 2022

Award:

1. 台灣癌症臨床研究發展基金會優秀論文獎, 2022

Curriculum Vitae

Name Wei-Chen Lu 魯維丞

Birthday June 21, 1982

Institutional Address Oncology Center and Department of Oncology,
National Taiwan University Hospital, Yunlin branch
No.95, 19th Neighborhood, Lianshih, Huwei Township, Yunlin
County 63247, Taiwan
Tel: 05-6330002
Email: b89401007@ntu.edu.tw



Education	Degree	Institution	Year
	M.D.	College of Medicine, National Taiwan University	2000-20
Work Experience	Position	Institution	Time
	Director	Division of Medical Oncology, Department of Oncology, National Taiwan University Hospital Yunlin Branch	2021 Au
	Vice Director	Oncology Center, National Taiwan University Hospital Yunlin Branch,	2016-
	Attending Physician , Medical Oncology	Department of Oncology, National Taiwan University Hospital Yunlin Branch	2014 Jul
	Fellow, Medical Oncology	Department of Oncology, National Taiwan University Hospital	2011 Jul 2014 Jun
	Resident, Internal Medicine	Department of Internal Medicine, National Taiwan University Hospital	2008 Jul 2011 Jun

Summary of

Time

qualification	Board of Medical Oncology	2013-
	Board of Internal Medicine	2011-
Professional		Time
Membership	European Society for Medical Oncology(ESMO)	2017-
	American Society of Clinical Oncology(ASCO)	2013-
	Taiwan Oncology Society(TOS)	2011-
	Society of Internal Medicine of Taiwan	2011-
Awards	第 27 屆台灣癌症聯合學術年會臨床組優良論文獎(2022)	
Clinical	head and neck cancer, nasopharyngeal carcinoma, esophageal cancer,	
Interest	lung cancer, GI cancer, prostate cancer	

Publication:

1. Jia-Zheng Huang, **Wei-Chen Lu**, Bo-Ching Lee, Exposed Embolic Coils Observed in a 64-Year-Old Male With Head and Neck Cancer Following Transarterial Embolization for Carotid Blowout Syndrome, Case Rep Oncol Med. 2024 May 13:2024:7925511
2. Hsing-Wu Chen, Yao-Wen Kuo, Chung-Yu Chen, Chin-Hao Chang, Su-Mei Wang, Ying-Chun Chien, **Wei-Chen Lu**, Jo-Pai Chen, Cheng-Yu Chang, Yu-Feng Wei, Shih-Chieh Chang, Chin-Chung Shu, Jann-Yuan Wang, Wei-Yu Liao, Hao-Chien Wang, Chong-Jen Yu, Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy, Oncologist. 2024 Jan 16
3. Hung-Ming Wang, Pei-Jen Lou, Muh-Hwa Yang, Tein-Hua Chen, Ming-Yu Lien, Jin-Ching Lin, Jo-Pai Chen, **Wei-Chen Lu**, Hsueh-Ju Lu, Tai-Lin Huang, Chia-Jui Yen, Shang-Yin Wu, Hui-Ching Wang, and Meng-Che Hsieh, Cetuximab Treatment

beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08), Target Oncol. 2024; 19(1): 51–58.

4. Hsueh-Ju Lu MD, PhD, Meng-Che Hsieh MD, Hung-Ming Wang MD, Jason Chia-Hsun Hsieh MD, PhD, Chia-Jui Yen MD, PhD, Shang-Yin Wu MD, Huai-Cheng Huang MD, Hui-Ching Wang MD, Pen-Yuan Chu MD, Tien-Hua Chen MD, Chih-Yen Chien MD, Tai-Lin Huang MD, PhD, Yi-Fang Chang MD, PhD, Chun-Hung Hua MD, Ming-Yu Lien MD, PhD, Jo-Pai Chen MD, **Wei-Chen Lu** MD, Jin-Ching Lin MD, PhD, Chen-Chi Wang MD, Yi-Chun Liu MD, Muh-Hwa Yang MD, PhD, Pei-Jen Lou MD, PhD, Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database, Head and Neck 2024

5. Chou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang, Bo-Wen Lin, Hong-Hwa Chen, Yao-Yu Hsieh, Hung-Chih Hsu, Meng-Che Hsieh, Tao-Wei Ke, Feng-Che Kuan, Chih-Chien Wu, **Wei-Chen Lu**, Yu-Li Su, Yi-Hsin Liang, Joe-Bin Chen, Hsuan-Yuan Huang, Hsiang-Lin Tsai, and Jaw-Yuan Wang, Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry, Am J Cancer Res. 2023; 13(12): 6333–6345

6. Yu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang, Bo-Wen Lin, Hong-Hwa Chen, Yao-Yu Hsieh, Hung-Chih Hsu, Meng-Che Hsieh, Feng-Che Kuan, Chih-Chien Wu, **Wei-Chen Lu**, Yu-Li Su, Yi-Hsin Liang, Joe-Bin Chen, Shuan-Yuan Huang, Ching-Wen Huang, Jaw-Yuan Wang, Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study,

Nutrients. 2023 Jun 30;15(13):2971. doi: 10.3390/nu15132971.

7. **Wei-Chen Lu**, Wei-Li Ma, Hsu Wu, Fu-Jen Hsueh, Hsing-Wu Chen, Keng-Man Chiang, Tsui-Mai Kao, Jo-Pai Chen , Beyond The EXTREME Study: Treatment Decisions for Patients with Head and Neck Squamous Cell Carcinoma Which Progress during or within 6 months after Completion of Concurrent Chemoradiotherapy, *2022 TJCC poster presentation*

8. Muh-Hwa Yang, Chen Tien Hua, Meng-Che Hsieh, Huai-Cheng Huang, Chih-Yen Chien, Tai-Lin Huang, Chun-Hung Hua, Ming-Yu Lien, Hui-Ching Wang, Hsueh-Ju Lu, Chia-Jui Yen, Shang-Yin Wu, Jo-Pai Chen, **Wei-Chen Lu**, Jin-Ching Lin, Chen-Chi Wang, Yi-Chun Liu, Hung-Ming Wang, Jason, Chia-Hsun Heieh, Pei-Jen Lou, A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen ASCO 2022 poster *Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) e18013-e18013*

9. **Wei-Chen Lu**, Wei-Li Ma, Hsu Wu, Fu-Jen Hsueh, Jo-Pai Chen, Beyond The EXTREME Study: Extremely Poor Prognosis for Patients with Head and Neck Squamous Cell Carcinoma Which Progress within 3 months after Completion of Concurrent Chemoradiotherapy, *2019 TJCC e-poster*

10. **Wei-Chen Lu**, Chia-Chi Lin, James Chih-Hsin Yang, Angiokinase Inhibitors in Non-small Cell Lung Cancer. *Clinical Investigation, (2015) 5(1), 47–59*

Curriculum Vitae

Updated on 02/Oct/2024

POSITION TITLE:

Dr. Jason Chia-Hsun Hsieh, M.D., M.Sc., Ph.D..

Medical Oncologist

Professor of Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan

OFFICE ADDRESS:

Division of Oncology, Department of Internal Medicine,

Chang Gung Memorial Hospital-Linkou Branch

No 5, Fu-Shin St., GuiShan Dist., Taoyuan City, 333423, Taiwan (R.O.C)

Email: wisdom5000@gmail.com

wisdom3000cgmh@gmail.com or wisdom5000@adm.cgmh.org.tw

Research Interests/fields:

Circulating tumor cells, Liquid biopsy, Neuroendocrine tumor, Head and neck cancer, Liver cancer, Esophageal cancer, Biomedical Engineering



Dr. Jason Chia-Hsun Hsieh is a distinguished Medical Oncologist and Professor of Medicine at Chang Gung Memorial Hospital at Linkou and Chang Gung University in Taiwan. With expertise in diverse areas, such as circulating tumor cells, microRNA, and various cancer types (mainly head and neck cancer, neuroendocrine tumors, and liver cancers), he has been instrumental in advancing cancer research. Dr. Hsieh earned his Medical Doctor's Degree and Master's in Medical Science from China Medical University (Taiwan), followed by a Ph.D. from Chang Gung University, and has been an editorial board member for esteemed journals like "PLoS ONE," "BMC Cancer," "Frontiers in Oncology," and "Cancer Medicine." Demonstrating leadership, he has served as the Taiwan Association of Cancer Research (TACR) president since 2022. Dr. Hsieh is affiliated with Chang Gung University and holds certifications from prominent medical societies. His impactful career is defined by exceptional medical knowledge, leadership, and contributions to the field.

EDUCATION, RESEARCH, AND PROFESSIONAL EXPERIENCE:

1996-	Medical Doctor Degree, China Medical University, Taichung, Taiwan
2004-2006	Master's Degree of Medical Science, China Medical University, Taichung, Taiwan
2006-2009	Residency in the Department of Internal Medicine, Chang Gung Memorial

	Hospital (CGMH), Taoyuan, Taiwan
2009-2011	Clinical Fellowship in Division of Medical Oncology, Department of Internal Medicine, CGMH, Taiwan
2011-2012	Hospice Service Care Training certificated
2011-present	Physician Attending in Division of Medical Oncology, Department of Internal Medicine, CGMH, Taiwan
2011-2016	Ph.D. training, Chang Gung University, Taiwan
2011-present	Paul Carbone Clinical Trial Design Training Program, Taiwan
2012-December	MD Anderson J-HOPE Program (Japan), Clinical trial Design Training. Japan
2014-November	Training Program in Oxford University, London, United Kingdom
2014-2018	Assistant Professor, Chang Gung Memorial Hospital
2016-June-present	Invited Editorial Board Member of the Journal of “ <i>Current Updates in Otolaryngology</i> ” and “ <i>Journal of Ear, Nose and Throat Disorders</i> ”
2017 June	Ph.D. degree, Chang Gung University, Taiwan
2018 Aug-2021 Jun	Associate Professor, Chang Gung Memorial Hospital
2018 Oct-present	Deputy Director of Medical Humanities, Chang Gung Memorial Hospital, Linkou
2019 Jan-present	Academic Editor, <i>PLoS ONE</i> (2024 Impact factor: 3.752)
2019 June-present	Editorial board member, <i>Clinical Gastroenterologist International</i>
2020 Feb-present	Associate Editor, <i>BMC Cancer</i> (2024 Impact factor: 3.4)
2020 April-2024 July	Director, Division of Hematology-Oncology, New Taipei Municipal TuCheng Hospital
2020 April-2024 July	Associate Editor, <i>Frontiers in Oncology</i> (2024 Impact factor: 3.5)
2020 April-2024 July	Deputy Director of Cancer Committee, New Taipei Municipal TuCheng Hospital
2021 July-present	Professor at Chang Gung Memorial Hospital
2024 July-present	Associate Editor, <i>Cancer Medicine</i> (2024 Impact factor: 4.7)

AFFILIATIONS

1. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital (Linkou), Taoyuan 333, Taiwan
2. College of Medicine, Chang Gung University, Taoyuan 333, Taiwan

BOARD CERTIFICATES

2009	Society of Internal Medicine, Republic of China
2011	Society of Chinese Oncology, Republic of China
2012	Member of Taiwan Academy of Hospice Palliative Medicine

2012 Member of Taiwan Society of Cancer Palliative Medicine

2013 Member of American Academy of Cancer Research

2014 Member of Taiwan Head and Neck Society

Editorial Board, Academic Editor, “*PLoS ONE*”

Editorial Board, Associate Editor, “*BMC Cancer*”

Editorial Board, Associate Editor, “*Frontiers in Oncology*”

Editorial Board Member, “*Clinical Gastroenterologist International*”

Editorial Board, Associate Editor, “*Cancer Medicine*” (since 2024 Aug.)

PUBLICATIONS

1. Chia-Hsun Hsieh(第一作者), John W. C. Chang, Jia-Juan Hsieh, Todd Hsu, Shiu-Feng Huang, Chun-Ta Liao, Hung-Ming Wang* "Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area." HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 2011 Dec;33(12):1758-64. doi: 10.1002/hed.21665. Epub 2011 Jan 31. (2022 SCIE, IF: 2.9, OTORHINOLARYNGOLOGY: 8/43 = 18.6%)
2. John Wen-Cheng Chang, Nien-Chih Wei, Hung-Ju Su, Jie-Len Huang, Tse-Ching Chen, Yi-Cheng Wu, Chih-Teng Yu, Ming-Mo Hou, Chia-Hsun Hsieh, Jia-Juan Hsieh, Chiao-En Wu, Hsin-Yi Cheng, Todd Hsu and Tzu-Hao Wang* “Comparison of Genomic Signatures of Non-small Cell Lung Cancer Recurrence between Two Microarray Platforms.” ANTICANCER RESEARCH 2012 Apr;32(4):1259-65. [CMRPG380761, CMRPG3B0081] (2022 SCIE IF: 2.0, Oncology 233/317 = 73.5%)
3. Po-Jung Su, Chia-Hsun Hsieh, Tsai-Sheng Yang* “Leptomeningeal carcinomatosis from a Primary Colon Cancer Patient.” Journal of Cancer Research and Practice. 27(3),113-116, 2011.
4. Chia-Hsun Hsieh(第一作者), Po-Jung Su, Chien-An Hsieh, Chia-Hung Yang, Chaung-Chi Liaw* “ST-segment Elevation Acute Myocardial Infarction after 5-fluorouracil infusion: one case report and literature review.” Journal of Cancer Research and Practice. 28(1),28-34, 2012.
5. Chia-Hsun Hsieh(第一作者), Cheng-lung Hsu, Cheng-Hsu Wang, Chaung-Chi Liaw, Jen-Shi Chen, Hsien-Kun Chang, Tsai-Shen Yang, John Wen-Cheng Chang; Yung-Chang Lin; Chi-Ting Liao, Ngan-Ming Tsang, Joseph Tung-Chieh Chang, Shu-Hang Ng, Hung-Ming Wang* “Cisplatin, Tegafur-Uracil (UFUR) and Leucovorin Plus Mitomycin C as an Outpatient Regimen for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Trial.” Biomedical Journal, Sep-Oct 2013;36(5):229-36. doi: 10.4103/2319-4170.113375. (2022 SCIE, IF: 5.5, Biochemistry & Molecular biology: 70/285 = 24.56%)
6. Cheng, W. H., Kao, C. Y., Hung, Y. S., Su, P. J., Hsieh Jason Chia-Hsun, Chen, J. S., Wang, H. M., Chou, W. C.* “Validation of a palliative prognostic index to predict life expectancy for terminally ill cancer patients in a hospice consultation setting in Taiwan.” Asian Pacific Journal of Cancer Prevention. 2012;13(6):2861-6. doi: 10.7314/apjcp.2012.13.6.2861.
7. Shih-Siou Wang, Song-Bin Huang(共同第一作者), Chia-Hsun Hsieh, Yung Chang Lin, Chao-Sung Lai, Min-Hsien Wu* “An integrated microfluidic cell culture system for high-throughput perfusion three-dimensional cell culture-based assays: Effect of cell culture model on the results of chemosensitivity

- assays.” LAB ON A CHIP 2013 Mar 21;13(6):1133-43. doi: 10.1039/c2lc41264k. [NSC100-2221-E-182-025, CMRPD2A0021] (2022 SCIE IF: 6.1, BIOCHEMICAL RESEARCH METHODS 7/77 = 9.09%)
8. Song-Bin Huang, Min-Hsien Wu(共同第一作者), Yen-Heng Lin, Chia-Hsun Hsieh, Chih-Liang Yang, Hung-Chih Lin, Ching-Ping Tseng and Gwo-Bin Lee* “High-purity and label-free isolation of circulating tumor cells (CTCs) after conventional negative selection-based CTC isolation process in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force.” 2013. LAB ON A CHIP 13(7): 1371-1383. [(NSC101-2120-M-007-014, NSC101-2218-E-007-006, NSC101-2221-E-182-001-MY3, NSC99-2632-B-182-001-MY3, CMRPG3B0971] (2022 SCIE IF: 6.1, BIOCHEMICAL RESEARCH METHODS 7/77 = 9.09%)
 9. Chia-Hsun Hsieh, Hung-Chih Lin, Hung-Chih Hsu (共同第一作者), Hung-Ming Wang, Chi-Ya Huang, Min-Hsien Wu and Ching-Ping Tseng* “A negative selection system PowerMag for enhanced detection of EpCAM positive and negative circulating tumor cells: implication in disease progression monitoring.” 2013. CLINICA CHIMICA ACTA 2013 Apr 18;419:77-84. doi: 10.1016/j.cca.2013.01.018. Epub 2013 Feb 13.[NSC 99-2632-B-182-001-MY3, 99-2628-B-182-001-MY3, CMRPD180423, CMRPD1B0391, EMRPD1A0511, EMRPD1C0121] (2022 SCIE IF: 5.0, MEDICAL LABORATORY TECHNOLOGY: 5/29 = 17.24%)
 10. Hsu, Cheng-Lung, Chan, Sheng-Chieh, Chang, Kai-Ping, Lin, Tung-Liang, Lin, Chien-Yu, Hsieh, Chia-Hsun, Huang, Shiang-Fu, Tsang, Ngan-Ming, Lee, Li-Yu, Ng, Shu-Hang, Wang, Hung-Ming* "Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma." ORAL ONCOLOGY 2013 Jun;49(6):620-5. doi: 10.1016/j.oraloncology.2013.02.006. Epub 2013 Mar 5. (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
 11. Yu-Shin Hung, Jin-Hou Wu, Hung Chang, Po-Nan Wang, Chen-Yi Kao, Hung-Ming Wang, Chi-Ting Liao, , Jen-Shi Chen, Yung-Chang Lin, Po-Jung Su, Chia-Hsun Hsieh, Wen-Chi Chou* "Characteristics of Patients with Hematologic Malignancies Who Received Palliative Care Consultation Services in a Medical Center." American Journal of Hospice & Palliative Medicine. 2013 Dec;30(8):773-80. doi: 10.1177/1049909112471423. Epub 2013 Jan 8. (2022 SCIE:1.9, HEALTH CARE SCIENCES & SERVICES:101/166 = 60.84%)
 12. Kwo C. Lee, Wen-Cheng Chang, Wen-Chi Chou, Po-Jung Su, Chia-Hsun Hsieh, Jen-Shi Chen and Siew Tzuh Tang* “Longitudinal Changes and Predictors of Caregiving Burden While Providing End-of-Life Care for Terminally Ill Cancer Patients.” JOURNAL OF PALLIATIVE MEDICINE. 2013 Jun;16(6):632-7. doi: 10.1089/jpm.2012.0499. Epub 2013 Apr 4. [NHRI-EX94-9806PC, NHRI-EX101-99006PI, NSC99-2628-B-182-031-MY2] (2022 SCIE IF: 2.8, HEALTH CARE SCIENCES & SERVICES 56/105 = 53.33%)
 13. Hung-Ming Wang, Cheng-Lung Hsu, Chia-Hsun Hsieh, Kang-Hsing Fan, Chien-Yu Lin, Joseph Tung-Chieh Chang, Shiang-Fu Huang, I-How Chen, Chun-Ta Liao, Shu-Kung Ng* “Concurrent Chemoradiotherapy Using Cisplatin, Tegafur, and Leucovorin for Advanced Squamous Cell Carcinoma of the Hypopharynx and Oropharynx.” Biomedical Journal. May-Jun 2014;37(3):133-40. doi: 10.4103/2319-4170.117893. (2022 SCIE, IF: 5.5, Biochemistry & Molecular biology: 70/285 = 24.56%)
 14. Chiao-En Wu, Chia-Hsun Hsieh, Ch ofeng-Jen Chang, Jiun-Ting Yeh, Tseng-tong Kuo, Chih-Hsun Yang,

- Yung-Feng Lo, Kun-Ju Lin, Yung-Chang Lin, John W Chang* “Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy.” JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION. 2015 May;114(5):415-21. doi: 10.1016/j.jfma.2013.06.018. Epub 2013 Aug 19. PubMed PMID: 23969039. (2022 SCIE, IF: 3.2, MEDICINE, GENERAL & INTERNAL 69/167 = 41.32%)
15. Tang ST, Liu LN, Lin KC, Chung JH, Hsieh Chia-Hsun, Chou WC, Su PJ* “Trajectories of the Multidimensional Dying Experience for Terminally Ill Cancer Patients.” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2014 Nov;48(5):863-74. doi: 10.1016/j.jpainsymman.2014.01.011. Epub 2014 Apr 15 [NSC98-2314-B-182-052, NSC99-2628-B-182-031-MY2, NHRIEX102-10208PI] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 16. Tang ST, Chang WC, Chen JS, Su PJ, Hsieh Chia-Hsun, Chou WC* “Trajectory and predictors of quality of life during the dying process: roles of perceived sense of burden to others and posttraumatic growth.” SUPPORTIVE CARE IN CANCER 2014 Nov;22(11):2957-64. doi: 10.1007/s00520-014-2288-y. Epub 2014 May 28.[NSC 98-2314-B-182-052, NSC99-2628-B-182-031-MY2, NHRI-EX103-10208PI] (2022 SCIE, IF: 3.1, REHABILITATION: 15/68 = 22.06%)
 17. Chia-Hsun Hsieh(第一作者), Hung-Chih Lin, Chi-Ya Huang, Hsung-Ling Hsu, Min-Hsien Wu, Chia-Lin Lee, Min-Chi Chen, Hung-Ming Wang, Ching-Ping Tseng* “Prognostic Value of Circulating Tumor Cells with Podoplanin Expression in Patients with Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma.” HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2015 Oct;37(10):1448-55. doi: 10.1002/hed.23779. Epub 2014 Jul 24. (2022 SCIE, IF: 2.9, OTORHINOLARYNGOLOGY: 8/43 = 18.6%)
 18. Chang JW, Hou MM, Hsieh JJ, Cheung YC, Wang HM, Chen JS, Wang CH, Chen CH, Yeh KY, Ou LY, Hsieh Chia-Hsun, Wu HD, Chen YT, Chang IC, Huang SF* “Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.” Biomedical Journal. 2015 May-Jun;38(3):221-8. doi: 10.4103/2319-4170.138320.[DOH96-TD-D-113-040, NHRI 96-A1-MG-PP-04, NHRI-A1-MG-98-PP-04, NSC97-2320-B-400-006-MY3] (2022 SCIE, IF: 5.5, Biochemistry & Molecular biology: 70/285 = 24.56%)
 19. Tang ST, Lin KC, Chen JS, Chang WC, Hsieh Chia-Hsun, Chou WC* “Threatened with death but growing: changes in and determinants of posttraumatic growth over the dying process for Taiwanese terminally ill cancer patients.” PSYCHO-ONCOLOGY. 2015 Feb;24(2):147-54. doi: 10.1002/pon.3616. Epub 2014 Jul 5. [NSC 98-2314-B-182-052, NSC99-2628-B-182-031-MY2, NHRI-EX103-10208PI] (2022 SCIE, IF: 3.6, SOCIAL SCIENCES, BIOMEDICAL: 11/45 = 24.44%)
 20. Siew Tzuh Tang, Jen-Shi Chen, Wen-Chi Chou, Kuan-Chia Lin, Wen-Cheng Chang, Chia-Hsun Hsieh, Chiao-En Wu* “Prevalence of severe depressive symptoms increases as death approaches and is associated with disease burden, tangible social support, and high self-perceived burden to others.” SUPPORTIVE CARE IN CANCER. 2016 Jan;24(1):83-91. doi: 10.1007/s00520-015-2747-0. Epub 2015 May 3. [NSC 98-2314-B-182-052, NSC99-2628-B-182-031-MY2, NHRI-EX104-10208PI] (2022 SCIE, IF: 3.1, REHABILITATION: 15/68 = 22.06%)

21. Chia-Hsun Hsieh(第一作者), Yi-Dao Chen, Shiang-Fu Huang, Hung-Ming Wang, Min-Hsien Wu* “The Effect of Primary Cancer Cell Culture Models on The Results of Drug Chemosensitivity Assays: The Application of Perfusion Microbioreactor System as Cell Culture Vessel.” *Biomed Research International* 2015; 2015: 470283. Published online 2015 Jan 14. doi: 10.1155/2015/470283 [NSC 101-2221-E-182-001-MY3, NSC 103-2314-B-182A-064; CMRPD2C0102, CMRPG3D0211, CMRPG3B0973] (2021 SCIE, IF: 3.246, BIORECHNOLOGY & APPLIED MICROBIOLOGY 92/167 = 54.79%)
22. Tzu-Keng Chiu, Kin-Fong Lei, Chia-Hsun Hsieh, Hung-Bo Hsiao, Hung-Ming Wang, Min-Hsien Wu* “Development of Microfluidic-based Optical Sensing Device for Label-free Detection of Circulating Tumor Cells (CTCs) Through Their Lactic Acid Metabolism.” *SENSORS*. 2015 Mar 19;15(3):6789-806. doi: 10.3390/s150306789. [NSC 102-2221-E-182-019-MY2; CMRPD2C0101, CMRPD2C0102, CMRPD2D0041] (2022 SCIE: 3.9, INSTRUMENT & INSTRUMENTATION: 19/63 = 30.16%)
23. Chiao-En Wu, Chi-Wei Wang, Wen-Kuan Huang, Cheng-Ta Yang, Yi-Cheng Wu, Ming-Mo Hou, Chia-Hsun Hsieh, Jia-Juan Hsieh, Hsin-Yi Cheng, Todd Hsu and John Wen-Cheng Chang* “Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection.” *JAPANESE JOURNAL OF CLINICAL ONCOLOGY*. 2015 Mar;45(3):267-73. doi: 10.1093/jjco/hyu202. Epub 2014 Dec 5. [CMRPG380761, CMRPG3B0081, CMRPG3B0082] (2022 SCIE, IF: 2.4, ONCOLOGY:189/241 = 78.42%)
24. Jason Chia-Hsun Hsieh(第一作者), Cheng-Lung Hsu, Shu-Hang Ng, Cheng-Hsu Wang, Kuan-Der Lee, Chang-Hsien Lu, Yi-Fang Chang, Ruey-Kuen Hsieh, Kun-Huei Yeh, Chi-Huang Hsiao, Sheng-Yu Chen, Cheng-Ying Shiau, Hung-Ming Wang* “Gemcitabine plus Cisplatin for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma in Taiwan: A Multicenter Prospective Phase II Trial.” *JAPANESE JOURNAL OF CLINICAL ONCOLOGY*. 2015 Sep;45(9):819-27. doi: 10.1093/jjco/hyv083. Epub 2015 Jun 8. (2022 SCIE, IF: 2.4, ONCOLOGY:189/241 = 78.42%)
25. Tang ST, Hsieh Chia-Hsun, Chiang MC, Chen JS, Chang WC, Chou WC, Hou MM* ”Impact of high self-perceived burden to others with preferences for end-of-life care and its determinants for terminally ill cancer patients: a prospective cohort study” *PSYCHO-ONCOLOGY*. 2017 Jan;26(1):102-108. doi: 10.1002/pon.4107. Epub 2016 Mar 7. [NSC 98-2314-B-182-052, 99-2628-B-182-031-MY2; NHRI-EX104-10208PI] (2022 SCIE, IF: 3.6, SOCIAL SCIENCES, BIOMEDICAL: 11/45 = 24.44%)
26. Liao CT, Fan KH, Kang CJ, Lin CY, Chang JT, Tsang NM, Huang BS, Chao YK, Lee LY, Hsueh C, Wang HM, Liao CT, Hsu CL, Hsieh Chia-Hsun, Ng SH, Lin CH, Tsao CK, Fang TJ, Huang SF, Chang KP, Yen TC* “Clinical Outcomes of Patients with Resected Oral Cavity Cancer and Simultaneous Second Primary Malignancies.” *PLoS One*. 2015 Sep 3;10(9):e0136918. doi: 10.1371/journal.pone.0136918. eCollection 2015. (2022 SCIE, IF: 3.7, MULTIDISCIPLINARY SCIENCES: 26/73 = 35.62%)
27. Hung-Chih Lin, Miaw-Jene Liou, Hsung-Ling Hsu, Jason Chia-Hsun Hsieh, Yi-An Chen, Ching-Ping Tseng, and Jen-Der Lin* “Combined analysis of circulating epithelial cells and serum thyroglobulin for differentiating disease status in the patients with papillary thyroid carcinoma” *Oncotarget*. 2016 Mar 29; 7(13): 17242–17253. Published online 2015 Dec 13. doi: 10.18632/oncotarget.6587 [NSC99-2632-B-182-001-MY3, MOST102-2628-B-182-009-MY3, MOST102-2628-B-182-010-MY3; CMRPD1C0551-3,

- CMRPD1B0391-3, CMRPD1E0181, EMRPD1E1491, NMRPD1B0312, CMRPG3B1943]
28. Tang, S. T., F. H. Wen, Chia-Hsun Hsieh, W. C. Chou, W. C. Chang, J. S. Chen, and M. C. Chiang*
 “Preferences for Life-Sustaining Treatments and Associations With Accurate Prognostic Awareness and Depressive Symptoms in Terminally Ill Cancer Patients' Last Year of Life” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2016 Jan;51(1):41-51.e1. doi: 10.1016/j.jpainsymman.2015.08.006. Epub 2015 Sep 18. [NHRI-EX104-10209PI, NSC 98-02314-B-182-052, NSC 99-2628-B-182-031-MY2] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 29. Chia-Hsun Hsieh, Ying-pin Hsu(共同第一作者), Huei-Tzu Chien, Chih-Hsiung Lai, Chung-Kan Tsao , Chun-Ta Liao, Chung-Jan Kang, Hung-Ming Wang, Joseph Tung-Chieh Chang, Shiang-Fu Huang* “Serum Markers of CYFRA 21-1 and C-Reactive Proteins in Oral Squamous Cell Carcinoma.” World Journal of Surgical Oncology. 2015; 13: 253.Published online 2015 Aug 21. doi: 10.1186/s12957-015-0656-9 (2022 SCIE IF: 3.2, SURGERY: 44/212 = 20.75%)
 30. CHENG-LUNG HSU, Yung-Chia Kuo, Yenlin Huang, Yin-Cheng Huang, Kar-Wai Lui, Kai-Ping Chang, Tung-Liang Lin, Hsien-Chi Fan, An-Chi Lin, Chia-Hsun Hsieh, Li-Yu Lee, Hung-Ming Wang, Hsin-Pai Li, and Yu-Sun Chang* “Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma” ONCOTARGET. 2015 Oct 13;6(31):31323-34. doi: 10.18632/oncotarget.5544. [CMRPG3C1931, CMRPG3C1932; MOST103-2314-B-182-041, MOST104-2314-B-182-036]
 31. Wen-Chi Chou, Yu-Shin Hung, Chen-Yi Kao, Po-Jung Su, Chia-Hsun Hsieh, Jen-Shi Chen, Chi-Ting Liao, Yung-Chang Lin, Chuang-Chi Liaw, Hung-Ming Wang* “Impact of palliative care consultative service on disease awareness for patients with terminal cancer” SUPPORTIVE CARE IN CANCER. 2013 Jul;21(7):1973-81. doi: 10.1007/s00520-013-1733-7. Epub 2013 Feb 21 (2022 SCIE, IF: 3.1, REHABILITATION: 15/68 = 22.06%)
 32. Chen-Yi Kao, Hung-Ming Wang, Shu-Chuan Tang, Kuan-Gen Huang, Tang-Her Jaing, Chien-Ying Liu, Keng-Hao Liu, Wen-Chi Shen, Jin-Hou Wu, Yu-Shin Hung, Hung-Chih Hsu, Jen-Shi Chen, Chi-Ting Liao, Yung-Chang Lin, Po-Jung Su, Chia-Hsun Hsieh, Wen-Chi Chou* ” Predictive Factors For Do-Not-Resuscitate Designation Among Terminally Ill Cancer Patients Receiving Care From a Palliative Care Consultation Service” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT 2014 Feb;47(2):271-82. doi: 10.1016/j.jpainsymman.2013.03.020. Epub 2013 Jul 12(2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 33. Hung-Ming Wang, Chien-Yu Lin, Chia-Hsun Hsieh, Cheng-Lung Hsu, Kang-Hsing Fan, Joseph Tung-Chieh Chang, Shiang-Fu Huang, Chung-Jan Kang, Chun-Ta Liao, Shu-Hang Ng, Tzu-Chen Yen* “Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer” JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION. 2017 Mar;116(3):185-192. doi: 10.1016/j.jfma.2016.03.005. Epub 2016 Apr 25. (2022 SCIE, IF: 3.2, MEDICINE, GENERAL & INTERNAL 69/167 = 41.32%)
 34. Shih-Hsin Chen, Hung-Ming Wang, Chien-Yu Lin, Joseph Tung-Chieh Chang, Chia-Hsun Hsieh, Chun-Ta Liao, Chung-Jan Kang, Lan-Yan Yang, Tzu-Chen Yen* "RGD-K5 PET/CT in patients with advanced head

- and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study." EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2016 Aug;43(9):1621-9. doi: 10.1007/s00259-016-3345-1. Epub 2016 Feb 27. [CMRPG3A0781-3] (2022 SCIE, IF: 9.1, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING: 7/135 = 5.19%).
35. Chia-Hsun Hsieh(第一作者), Hung-Chih Lin, Song-Bin Huang, Chuen Hsueh, Hsung-Ling Hsug, Hung-Ming Wang, Min-Hsien Wud, Ching-Ping Tseng, Jen-Der Lin* "Circulating epithelial cell enumeration facilitates the identification and follow-up of a patient with early stage papillary thyroid microcarcinoma: A case report." CLINICA CHIMICA ACTA. 2016 Feb 15;454:107-11. doi: 10.1016/j.cca.2015.12.030. Epub 2016 Jan 2. [NSC 99-2632-B-182-001-MY3, 99-2628-B-182-001-MY3, 11002-2628-B-182-009-MY3, 102-2628-B-182-010-MY3, 101-2314-B-182-038-MY2, NSC 101-2221-E-182-001-MY3, 102-2221-E-182-019-MY2, MOST 103-2314-B-182A-064; CMRPD1B0391-3, CMRPD1C0551-3, CMRPD1E0181, EMRPD1E1491, CMRPG3B1942, CMRPD2C010, CMRPG3D0211-2, CMRPG3B0973] (2022 SCIE IF: 5.0, MEDICAL LABORATORY TECHNOLOGY: 5/29 = 17.24%)
 36. Tang ST, Chang WC, Chen JS, Chou WC, Hsieh Chia-Hsun, Chen CH* "Associations of prognostic awareness/acceptance with psychological distress, existential suffering, and quality of life in terminally ill cancer patients' last year of life" PSYCHO-ONCOLOGY. 2016 Apr;25(4):455-62. doi: 10.1002/pon.3943. Epub 2015 Aug 17 (2022 SCIE, IF: 3.6, SOCIAL SCIENCES, BIOMEDICAL: 11/45 = 24.44%)
 37. Siew Tzuh Tang, Jen-Shi Chen, Wen-Chi Chou, Wen-Cheng Chang, Chiao-En Wu., Chia-Hsun Hsieh, Ming-Chu Chiang and Mei-Ling Kuo* "Longitudinal Analysis of Severe Anxiety Symptoms in the Last Year of Life Among Patients With Advanced Cancer: Relationships With Proximity to Death, Burden, and Social Support." Journal of the National Comprehensive Cancer Network 2016 Jun;14(6):727-34. (2022 SCIE, IF: 13.4, ONCOLOGY: 19/241 = 7.88%)
 38. Wang HY, Hsieh Chia-Hsun, Wen CN, Wen YH, Chen CH, Lu JJ* "Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers." PLoS One. 2016 Jun 29;11(6):e0158285. doi: 10.1371/journal.pone.0158285. eCollection 2016. (2022 SCIE, IF: 3.7, MULTIDISCIPLINARY SCIENCES: 26/73 = 35.62%)
 39. Hung-Ming Wang, Tung-Liang Lin, Yung-Chia Kuo, Hsin-Pai Li, Kai-Ping Chang, Chien-Yu Lin, Hsien-Chi Fan, An-Chi Lin, Jason Chia-Hsun Hsieh, Ngan-Ming Tsang, Li-Yu Lee, Sheng-Chieh Chan, Kar-Wai Lui, Yu-Sun Chang, and Cheng-Lung Hsu* "Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis." Oncotarget. 2016 Aug 16;7(33):53217-53229. doi: 10.18632/oncotarget.10676. [CMRPG360251-3, CMRPG391381-3, CMRPG3C1931-3; MOST 103-2314-B-182-041, MOST 104-2314-B-182-036]
 40. Yung-Yueh Su, Shih-Shin Chen, Chia-Hsun Hsieh, Chun-Ta Liao, Chien-Yu Lin, Chung-Jan Kang, Tzu-Chen Yen* "Defining risk groups of patients with cancer of unknown primary site and cervical nodal

- metastases by F-18 fluorodeoxyglucose positron emission tomography and computed tomography imaging” *KAOHSIUNG JOURNAL OF MEDICAL SCIENCES*. 2016 Aug;32(8):407-13. doi: 10.1016/j.kjms.2016.07.004. Epub 2016 Aug 3. (2022 SCIE IF: 3.3, MEDICINE, RESEARCH & EXPERIMENTAL: 81/136 = 59.56%).
41. Tzu-Keng Chiu, Wen-Pin Chou, Song-Bin Huang, Hung-Ming Wang, Yung-Chang Lin, Min-Hsien Wu*, Chia-Hsun Hsieh* (通訊作者) “Application of optically-induced-dielectrophoresis in microfluidic system for purification of circulating tumour cells for gene expression analysis- Cancer cell line model”. *Scientific Reports*. 2016 Sep 9;6:32851. doi: 10.1038/srep32851. [CMRPD2C0101-2, CMRPG3E1632, CMRPG3E0512, CMRPD0041-2]. (2022 SCIE, IF: 4.6, MULTIDISCIPLINARY SCIENCES: 22/73 = 30.14%)
 42. Po-Jung Su, Min-Hsien Wu, Hung-Ming Wang, Chia-Lin Lee, Wen-Kuan Huang, Chiao-En Wu, Hsien-Kun Chang, Yin-Kai Chao, Chen-Kan Tseng, Tzu-Keng Chiu, Nina Ming-Jung Lin, Siou-Ru Ye, Jane Ying-Chieh Lee, Chia-Hsun Hsieh* (通訊作者) “Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy ” *Scientific Reports*. 2016 Aug 17;6:31423. doi: 10.1038/srep31423. [MOST 103-2314-B-182A-064-, 105-2314-B-182A-030-;CMRPG3E1631-32, CMRPG3E0511-12, NMRPD1E011, CMRPD2D0041-42]. (2022 SCIE, IF: 4.6, MULTIDISCIPLINARY SCIENCES: 22/73 = 30.14%)
 43. W.K. Huang, T.T. Kuo, C.E. Wu, H.Y. Cheng, Chia-Hsun Hsieh, J.J. Hsieh, Y.C. Shen, M.M. Hou, T. Hsu, J.W. Chang* ”A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan”. *Asia-Pacific Journal of Clinical Oncology*. 2016 Dec;12(4):403-408. doi: 10.1111/ajco.12574. Epub 2016 Aug 4. (2022 SCIE IF: 1.9, ONCOLOGY: 214/241 = 88.79%)
 44. Hung-Ming Wang, Chun-Ta Liao, Tzu-Chen Yen, Shu-Jen Chen, Li-Yu Lee, Chia-Hsun Hsieh, Chien-Yu Lin, and Shu-Hang Ng* "Clues toward precision medicine in oral cavity squamous cell carcinoma: utility of next-generation sequencing for the prognostic stratification of high-risk patients harboring neck lymph node extracapsular extension" *Oncotarget*. 2016 Sep 27;7(39):63082-63092. doi: 10.18632/oncotarget.11762. [NMRPG3B0403, CIRPG1E0012, CMRPG3C0833, CMRPG3D1071]
 45. Pei-Yu Hsu, Sien Hung Yang, Ngan Ming Tsang, Kang-Hsing Fan, Chia-Hsun Hsieh, Jr-Rung Lin, Ji Hong Hong, Yung Chang Lin, Hsing-Yu Chen, Cheng-Tao Yang, Ching-Wei Yang and Jiun-Liang Chen* “Efficacy of Traditional Chinese Medicine in Xerostomia and Quality of Life During Radiotherapy for Head and Neck Cancer: A Prospective Pilot Study.” *Evidence-Based Complementary and Alternative Medicine*. 2016;2016:8359251. doi: 10.1155/2016/8359251. Epub 2016 Aug 21.[CMRPG3C0301] (2021 SCIE IF:

- 2.65, INTEGRATIVE & COMPLEMENTARY MEDICINE: 16/30= 51.67%)
46. Pei-Hung Chang, Kun-Yun Yeh, Cheng-Hsu Wang, Eric Yen-Chao Chen, Shih-Wei Yang, Wen-Chi Chou, Jason Chia-Hsun Hsieh*(通訊作者) “Impact of metformin on advanced head and neck cancer patients undergoing concurrent chemoradiotherapy.” HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 2017 Aug;39(8):1573-1577. doi: 10.1002/hed.24793. Epub 2017 Apr 27. (2022 SCIE, IF: 2.9, OTORHINOLARYNGOLOGY: 8/43 = 18.6%)
 47. Yap, Wing-Keen, Chang, Yu-Chuan, Tseng, Chen-Kan, Hsieh, Chia-Hsun, Chao, Yin-Kai, Su, Po-Jung, Hou, Ming-Mo, Yang, Chan-Keng, Pai, Ping-Ching, Lin, Ching-Rong, Hsieh, Cheng-En, Wu, Yao-Yu, Hung, Tsung-Min* “Predictive Value of Nodal SUVmax of Pretreatment FDG-PET Imaging in Patients with Esophageal Cancer”. DISEASES OF THE ESOPHAGUS. 2017 Aug 1;30(8):1-10. doi: 10.1093/dote/dox021. (2022 SCIE IF:2.6, Gastroenterology & Hepatology:71/93 = 76.34%)
 48. WC Chou, CL Lee, TS Yang, CY Huang, W Teng, YT Tseng, JS Chen, YC Lin, MM Hou, HH Chang, Jason CH Hsieh*(通訊作者) “Changes in the Serum α -Fetoprotein Level Predict Treatment Response and Survival in Hepatocellular Carcinoma Patients and Literature Review”. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION. 2018 Feb;117(2):153-163. doi: 10.1016/j.jfma.2017.03.010. Epub 2017 Apr 6. [N105-2314-B-182A-030-,CMRPG3E1631-2,CMRPG3E0512] (2022 SCIE, IF: 3.2, MEDICINE, GENERAL & INTERNAL 69/167 = 41.32%)
 49. Chia-Jung Liao, Chia-Hsun Hsieh(共同第一作者), Hung-Ming Wang, Wen-Pin Chou, Tzu-Keng Chiu, Jyun-Huan Chang, A.-Ching Chao* and Min-Hsien Wu* ” Isolation of label-free and viable circulating tumour cells (CTCs) from blood samples of cancer patients through a two-step process: negative selection-type immunomagnetic beads and spheroid cell culture-based cell isolation” RSC Advances, Issue 47, 2017,DOI 10.1039/C7RA03663A Issue in Progress [MOST 104-2628-E-182-002-MY3, 105-2314-B-182A-030, 104-2314-B-182-031-MY3; CMRPD2E0011-3, CMRPG3G0591-3, CMRPG3E0512, CMRPG3E1633] (2022 SCIE, IF: 3.9; Chemistry, Multidisciplinary: 74/178 = 41.57%)
 50. Chan SC, Cheng NM, Hsieh Chia-Hsun, Ng SH, Lin CY, Yen TC, Hsu CL, Wan HM, Liao CT, Chang KP, Wang JJ* ”Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy” Oncotarget. 2017 Mar 4;8(37):62606-62621. doi: 10.18632/oncotarget.15904. eCollection 2017 Sep 22. [NSC 99-2314-B-182A-095-MY3, 102-2314-B-182A-098-MY2, 104-2314-B-182A-084-MY3, 102-2314-B-182A-096, 102-2628-B-182A-012-MY3; CMRPG2E0191, CMRPG3C1912, CMRPG3C1913, CMRPG391391]
 51. Chia-Yen Hung, Tung-Liang Lin, Yung-Chia Kuo, Chia-Hsun Hsieh, Hung-Ming Wang, Cheng-Lung Hsu* “Progesterone analogues reduce plasma Epstein-Barr virus DNA load and improve pain control in recurrent/metastatic nasopharyngeal carcinoma patients under supportive care. “Biomedical Journal 2017 Aug;40(4):212-218. doi: 10.1016/j.bj.2017.06.006. Epub 2017 Jul 27. (2022 SCIE, IF: 5.5, Biochemistry &

Molecular biology: 70/285 = 24.56%)

52. Heng-Yuan Hsu, Yin-Kai Chao, Chia-Hsun Hsieh, Yu-Wen Wen, Hsien-Kun Chang, Chen-Kan Tseng, Yun-Hen Liu * “Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis.” ANNALS OF THORACIC SURGERY. 2016 Nov;102(5):1687-1693. doi: 10.1016/j.athoracsur.2016.05.026. Epub 2016 Jul 22. (2022 SCIE IF: 4.6, Surgery:23/212 = 10.85%)
53. Chun-Ta Liao, Yu-Wen Wen, Lan Yan Yang, Shu Ru Lee, Shu-Hang Ng, Tsang-Wu Liu, Sen-Tien Tsai, Ming-Hsui Tsai, Jin-Ching Lin, Peir-Rong Chen, Pei-Jen Lou, Cheng Ping Wang, Pen-Yuan Chu, Tzer-Zen Hwang, Yi-Shing Leum, Kuo-Yang Tsai, Shyuang-Der Terng, Tsung-Ming Chen, Cheng-Hsu Wang, Chih-Yen Chien, Wen-Cheng Chen, Li-Yu Lee, Chien-Yu Lin, Hung-Ming Wang, Chia-Hsun Hsieh, Chung-Kan Tsao, Tuan-Jen Fang, Shiang-Fu Huang, Chung-Jan Kang, Kai-Ping Chang, Tzu-Chen Yen* “Comparative clinical outcomes of Taiwanese patients with resected buccal and tongue squamous cell carcinomas.” ORAL ONCOLOGY. 2017 Apr;67:95-102. doi: 10.1016/j.oraloncology.2017.02.011. Epub 2017 Feb 20. (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
54. Cheng-En Hsieh, Kung-Chu Ho, Chia-Hsun Hsieh, Tzu-Chen Yen; Chun-Ta Liao, Hung-Ming Wang, Chien-Yu Lin* “Pretreatment Primary Tumor SUVmax on 18F-FDG PET/CT Images Predicts Outcomes in Patients With Salivary Gland Carcinoma Treated With Definitive Intensity-Modulated Radiation Therapy” CLINICAL NUCLEAR MEDICINE. 2017 Sep;42(9):655-662. doi: 10.1097/RLU.0000000000001740. (2022 SCIE IF: 10.6, RADIOLOGY,NUCLEAR MEDICINE & MEDICAL IMAGINE:4/135 = 2.96%)
55. Chao-Wei Lee, Sey-En Lin, Hsin-I Tsai, Po-Jung Su, Chia-Hsun Hsieh, Yung-Chia Kuo, Chang-Mu Sung, Cheng-Yu Lin, Chi-Neu Tsai, And Ming-Chin Yu* “Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma.” Oncology Letters. 2018 Jan;15(1):559-567. doi: 10.3892/ol.2017.7320. Epub 2017 Nov 1. [CMRPG3G0051; Ministry of Science and Technology NMRPG3F0321] (2022 SCIE IF:2.9 Oncology:163/241 = 67.63%)
56. Chang PH, Yeh KY, Wang CH, Chen EY, Yang SW, Huang JS, Chou WC, Jason Chia-Hsun Hsieh* (通訊作者)“Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.” HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 2017 Oct;39(10):1990-1996. doi: 10.1002/hed.24853. Epub 2017 Jul 7. [CMRPG3E1632-3,CMRPG2D0171-3, National Science Council Grants MOST105-2314-B-182A-030] (2022 SCIE, IF: 2.9, OTORHINOLARYNGOLOGY: 8/43 = 18.6%)
57. Wen-Chi Chou, Min-Hsien Wu, Pei-Hung Chang(共同第一作者), Hung-Chih Hsu, Wen-Kuan Huang, Chiao-En Wu, Jason Chia-Hsun Hsieh* (通訊作者)“A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.

- “International Journal of Biological Sciences 2018 Jan 12;14(2):137-146. doi: 10.7150/ijbs.23182.
eCollection 2018. [CMRPG3C1561,CMRPG3E0512, CMRPG3G0591,CMRPD 2D0041-
43,CMRPD2E0011-1 and MOST 105-2314-B-182A- 030-] (2022 SCIE IF:9.2, BIOCHEMISTRY &
MOLECULAR BIOLOGY: 31/285 = 10.88%)
58. Wing Keen Yap, Yu-Chuan Chang, Chia-Hsun Hsieh, Yin-Kai Chao, Chien-Cheng Chen, Ming-Chieh Shih, Tsung-Min Hung* “Favorable versus Unfavorable Prognostic Groups by Post-Chemoradiation FDG-PET Imaging in Node-positive Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Chemoradiotherapy. “EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2018 May;45(5):689-698. doi: 10.1007/s00259-017-3901-3. Epub 2017 Nov 30. (2022 SCIE, IF: 9.1, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING: 7/135 = 5.19%) .
 59. Wang, C. H., P. W. Huang, C. Y. Hung, S. H. Lee, C. Y. Kao, H. M. Wang, Y. S. Hung, P. J. Su, Y. C. Kuo, Chia-Hsun Hsieh, and W. C. Chou* “Clinical Factors Associated With Adherence to the Premedication Protocol for Withdrawal of Mechanical Ventilation in Terminally Ill Patients: A 4-Year Experience at a Single Medical Center in Asia.” American Journal of Hospice & Palliative Medicine. 2018 May;35(5):772-779. doi: 10.1177/1049909117732282. Epub 2017 Sep 21. (2022 SCIE:1.9, HEALTH CARE SCIENCES & SERVICES:101/166 = 60.84%)
 60. Liao, C. T., L. Y. Lee, C. Hsueh, C. Y. Lin, K. H. Fan, H. M. Wang, Chia-Hsun. Hsieh, S. H. Ng, C. H. Lin, C. K. Tsao, C. J. Kang, T. J. Fang, S. F. Huang, K. P. Chang, L. Y. Yang, and T. C. Yen* “Clinical Outcomes in pT4 Tongue Carcinoma are Worse than in pT3 Disease: How Extrinsic Muscle Invasion Should be Considered?” ANNALS OF SURGICAL ONCOLOGY. 2017 Sep;24(9):2570-2579. doi: 10.1245/s10434-017-5906-3. Epub 2017 Jun 3. (2022 SCIE:3.7, SURGERY:35/212 = 16.51%)
 61. Yap, Wing-Keen, Chang, Yu-Chuan, Tseng, Chen-Kan, Hsieh, Chia-Hsun, Chao, Yin-Kai, Su, Po-Jung, Hou, Ming-Mo, Yang, Chan-Keng, Pai, Ping-Ching, Lin, Ching-Rong, Hsieh, Cheng-En, Wu, Yao-Yu, Hung, Tsung-Min “Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer” DISEASES OF THE ESOPHAGUS.,2017 Aug 1;30(8):1-10. doi: 10.1093/dote/dox021. (2022 SCIE IF:2.6, Gastroenterology & Hepatology:71/93 = 76.34%)
 62. Wang, K., Y. Zhao, D. Chen, C. Huang, B. Fan, R. Long, Chia-Hsun Hsieh, J. Wang, M. H. Wu, and J. Chen* ”The Instrumentation of a Microfluidic Analyzer Enabling the Characterization of the Specific Membrane Capacitance, Cytoplasm Conductivity, and Instantaneous Young's Modulus of Single Cells” INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2017 Jun 19;18(6). pii: E1158. doi: 10.3390/ijms18061158.[National Basic Research Program of China (973 Program, Grant No. 2014CB744600), the National Natural Science Foundation of China (Grant No. 61431019, 61671430, 61571437), Key Projects of Chinese Academy of Sciences (QYZDB-SSW-JSC011), the Natural Science

- Foundation of Beijing (4152056), CMRPD2E0011-13] (2022 SCIE IF:5.6, BIOCHEMESTRY & MOLECULAR BIOLOGY:66/285 = 23.16%)
63. Chen, S. H., Y. C. Chang, T. L. Hwang, J. S. Chen, W. C. Chou, Chia-Hsun Hsieh, T. S. Yeh, J. T. Hsu, C. N. Yeh, J. H. Tseng, T. C. Chen, and T. C. Yen* "68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan" JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION. 2018 Jun;117(6):480-487. doi: 10.1016/j.jfma.2017.07.007. Epub 2017 Jul 20. (2022 SCIE, IF: 3.2, MEDICINE, GENERAL & INTERNAL 69/167 = 41.32%)
 64. Hsiu Chen, C., F. H. Wen, M. M. Hou, Chia-Hsun Hsieh, W. C. Chou, J. S. Chen, W. C. Chang, and S. T. Tang* "Transitions in Prognostic Awareness Among Terminally Ill Cancer Patients in Their Last 6 Months of Life Examined by Multi-State Markov Modeling" ONCOLOGIST. 2017 Sep;22(9):1135-1142. doi: 10.1634/theoncologist.2017-0068. Epub 2017 Jul 6. [NHRI-EX106-10208PI ,NSC99-2628-B-182-031-MY2,BMRP888] (2022 SCIE IF:5.8, ONCOLOGY:59/241 = 24.48%)
 65. Chang, P. H., C. H. Wang, E. Y. Chen, S. W. Yang, W. C. Chou, Jason Chia-Hsun Hsieh, F. C. Kuan, and K. Y. Yeh. "Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer" Chinese Journal of Cancer Research. 2017 Jun;29(3):172-178. doi: 10.21147/j.issn.1000-9604.2017.03.02. (2022 SCIE IF: 5.1, ONCOLOGY: 76/241 = 31.54%)
 66. Jen-Shi Chen, Fur-Hsing Wen, Wen-Cheng Chang, Chia-Hsun Hsieh, Wen-ChiChou, Ming-Mo Hou, Siew Tzuh Tang* "Accurate prognostic awareness facilitates, whereas better quality of life and more anxiety symptoms hinder end-of-life care discussions: a longitudinal survey study in terminally ill cancer patients' last six months of life." JOURNAL OF PAIN AND SYMPTOM MANAGEMENT 2018 Apr;55(4):1068-1076. doi: 10.1016/j.jpainsymman.2017.12.485. Epub 2017 Dec 29.[NHRI-EX106-10208PI, MOST104-2314-B-182-027-MY3, BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 67. Huang PW, Lin CY, Hsieh Chia-Hsun, Hsu CL, Fan KH, Huang SF, Liao CT, Ng SK, Yen TC, Chang JT, Wang HM* "A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx." Biomedical Journal. 2018 Apr;41(2):129-136. doi: 10.1016/j.bj.2018.04.003. Epub 2018 May 21. [CMRPG 360101-3] (2022 SCIE, IF: 5.5, Biochemistry & Molecular biology: 70/285 = 24.56%)
 68. Hsieh Chia-Hsun(第一作者) , Chen WM, Hsieh YS, Fan YC, Yang PE, Kang ST, Liao CT. "A Novel Multi-Gene Detection Platform for the Analysis of miRNA Expression." Scientific Reports. 2018 Jul 16;8(1):10684. doi: 10.1038/s41598-018-29146-7. [104-2314-B-182A-073-MY3, CMRPG3D1063, CMRPG3D1073, CMRPG3E1633, CMRPG3E0512, CMRPG3G0591-2]. (2022 SCIE, IF: 4.6, MULTIDISCIPLINARY SCIENCES: 22/73 = 30.14%)
 69. Chang, C. C., Wang, K., Zhang, Y., Chen, D., Fan, B., Hsieh Chia-Hsun., Wang, J., Wu, M. H. *(Co-

- corresponding author), Chen, J.* "Mechanical Property Characterization of Hundreds of Single Nuclei Based on Microfluidic Constriction Channel," CYTOMETRY PART A. 2018 Aug;93(8):822-828. doi: 10.1002/cyto.a.23386. Epub 2018 Jul 31. [National Basic Research Program of China (973 Program), Grant number: 2014CB744600, National Natural Science Foundation of China, Grant number: 61431019 and 61671430, Chinese Academy of Sciences Key Project, Grant number: QYZDB-SSW-JSC011, CMRPD2E0011-13, CMRPD2G0061-62] (2022 SCIE, IF: 3.7 BIOCHEMICAL RESEARCH METHODS: 26/77 = 33.77%)
70. Hung-Chih Hsu, Nina Lapke, Shu-Jen Chen, Yen-Jung Lu, Ren-Shiang Jhou, Chien-Yuh Yeh, Wen-Sy Tsai, Hsin-Yuan Hung, Jason Chia-Hsun Hsieh, Tsai-Sheng Yang, Tan Kien Thiam *, Jeng-Fu You * "PTPRT and PTPRD deleterious mutations and deletion predict bevacizumab resistance in metastatic colorectal cancer patients" Cancers (Basel) 2018 Sep 6;10(9). pii: E314. doi: 10.3390/cancers10090314.[CORPG3F0062, CMRPG3C1841] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
 71. Hsu CL, Lui KW, Chi LM, Kuo YC, Chao YK, Yeh CN, Lee LY, Huang Y, Lin TL, Huang MY, Lai YR, Yeh YM, Fan HC, Lin AC, Lu YJ, Hsieh Chia-Hsun, Chang KP, Tsang NM, Wang HM, Chang AY, Chang YS, Li HP* " Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma" JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2018 Sep 20;37(1):233. doi: 10.1186/s13046-018-0873-5.[CMRPG-3C1931~3, -3H0161, CPRPG-3F0011~2, CMRPG3E1131~2, CMRPD3E0071~2, CMRPD1G0471~2, MOST105-2314-B-182-063-MY2, MOST107-2314-B-182-056-MY2, MOST104-2320-B-182-033-MY3, MOST107-2320-B-182-033,EMRPD-1G0151, -1H027] (2022 SCIE, IF: 11.3, Oncology: 24/241 = 9.96%)
 72. Fur-Hsing Wen, , Jen-Shi Chen, , Po-Jung Su, , Wen-Cheng Chang, , Chia-Hsun Hsieh, Ming-Mo Hou, , Wen-Chi Chou, , Siew Tzuh Tang* "Terminally Ill Cancer Patients' Concordance Between Preferred Life-Sustaining Treatment States in Their Last Six Months of Life and Received Life-Sustaining Treatment States in Their Last Month: An Observational Study" JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2018 Oct;56(4):509-518.e3. doi: 10.1016/j.jpainsymman.2018.07.003. Epub 2018 Jul 17. [NHRI-EX107-10704PI, MOST 104-2314-B-182-027- MY3, BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 73. Wen FH, Chen JS, Chou WC, Hsieh Chia-Hsun, Chang WC, Shen WC, Tang ST* "Quality of Life and Psychological Distress Are Differentially Associated with Distinct Symptom-Functional States in Terminally Ill Cancer Patients' Last Year of Life" PSYCHO-ONCOLOGY. 2018 Sep;27(9):2111-2118. doi: 10.1002/pon.4775. Epub 2018 Jun 29. [NHRI-EX107-10704PI, MOST 104-2314-B-182-027- MY3, BMRP888] (2022 SCIE, IF: 3.6, SOCIAL SCIENCES, BIOMEDICAL: 11/45 = 24.44%)
 74. Fur-Hsing Wen, Jen-Shi Chen, Wen-Chi Chou, Chia-Hsun Hsieh, Wen-Cheng Chang, Ming-Mo Hou, Siew Tzuh Tang* "Distinct Patterns of Conjoint Symptom Distress and Functional Impairment in the Last Year of

- Life Predict Terminally Ill Cancer Patients' Survival” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2018 Jun;55(6):1443-1451.e2. doi: 10.1016/j.jpainsymman.2018.03.007. Epub 2018 Mar 13.[NHRI-EX107-10704PI, MOST 104-2314-B-182-027- MY3, BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
75. Po-Yu Chu, Chia-Jung Liao, Chia-Hsun Hsieh (共同第一作者), Hung-Ming Wang, Wen-Pin Chou, Ping-Hei Chen, Min-Hsien Wu* “Utilization of optically induced dielectrophoresis in a microfluidic system for sorting and isolation of cells with varied degree of viability: Demonstration of the sorting and isolation of drug-treated cancer cells with various degrees of anti-cancer drug resistance gene expression” SENSORS AND ACTUATORS B-CHEMICAL 10 December 2018, 283, 15 March 2019, Pages 621-631<https://doi.org/10.1016/j.snb.2018.12.047>[MOST 105-2221-E-182-028-MY3, MOST 104-2628-E-182-002-MY3; CMRPD2E0011-13, CMRPD2G0061-62, CMRPD2H0121] (2022 SCIE: 8.4, INSTRUMENT & INSTRUMENTATION: 1/63 = 1.59%)
 76. Wen FH, Chou WC, Chen JS, Chang WC, Hsieh Chia-Hsun, Tang ST* “Evolution and Predictors of Patient-Caregiver Concordance on States of Life-Sustaining Treatment Preferences over Terminally Ill Cancer Patients' Last Six Months of Life.” JOURNAL OF PALLIATIVE MEDICINE_2019 Jan;22(1):25-33. doi: 10.1089/jpm.2018.0307. Epub 2018 Sep 20. PubMed PMID: 30234418. [NHRI-EX107–10704PI, MOST 104-2314-B-182-027-MY3, BMRP888] (2022 SCIE IF: 2.8, HEALTH CARE SCIENCES & SERVICES 56/105 = 53.33%)
 77. Liao CJ, Hsieh Chia-Hsun, Chiu TK, Zhu YX, Wang HM, Hung FC, Chou WP, Wu MH* “An Optically Induced Dielectrophoresis (ODEP)-Based Microfluidic System for the Isolation of High-Purity CD45(neg)/EpCAM(neg) Cells from the Blood Samples of Cancer Patients-Demonstration and Initial Exploration of the Clinical Significance of These Cells.” Micromachines. 2018 Oct 31;9(11). pii: E563. doi: 10.3390/mi9110563. PubMed PMID: 30715062; PubMed Central PMCID: PMC6266761. (MOST104-2628-E-182-002-MY3, 105-2221-E-182-028-MY3; CMRPG3G0591-3, CMRPG3E1633, CMRPD2E0011-13, CMRPD2G0061-62, CMRPD2H0121) (2022 SCIE, IF: 3.4, CHEMISTRY, ANALYTICAL: 30/86 = 34.88%)
 78. Liao CT, Lee LY, Hsueh C, Lin CY, Fan KH, Wang HM, Hsieh Chia-Hsun, Ng SH, Lin CH, Tsao CK, Kang CJ, Fang TJ, Huang SF, Chang KP, Yang LY, Yen TC* “Pathological risk factors stratification in pN3b oral cavity squamous cell carcinoma: Focus on the number of positive nodes and extranodal extension.” ORAL ONCOLOGY. 2018 Nov;86:188-194. doi: 10.1016/j.oraloncology.2018.09.021. Epub 2018 Sep 28. PubMed PMID: 30409299. (PMRPG3H0071) (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
 79. Chang PH, Hsieh Jason Chia-Hsun, Yeh KY, Chen EY, Yang SW, Huang JS, Lai CH, Wu TH, Huang YM, Chang YS, Chou WC, Wang CH* “Prognostic nutritional index relevance in chemoradiotherapy for advanced oral cavity, oropharyngeal and hypopharyngeal cancer.” ASIA PACIFIC JOURNAL OF

- CLINICAL NUTRITION 2018;27(5):996-1001. doi: 10.6133/apjcn.032018.04.PubMed PMID: 30272847.
(2022 SCIE IF: 1.3, NUTRITION & DIETETIC: 77/88 =87.5%)
80. Chen CH, Chen JS, Wen FH, Chang WC, Chou WC, Hsieh Chia-Hsun, Hou MM, Tang ST* ” An Individualized, Interactive Intervention Promotes Terminally Ill Cancer Patients' Prognostic Awareness and Reduces Cardiopulmonary Resuscitation Received in the Last Month of Life: Secondary Analysis of a Randomized Clinical Trial.” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2019 Apr;57(4):705-714.e7. doi: 10.1016/j.jpainsymman.2019.01.002. Epub 2019 Jan 10.PubMed PMID: 30639758. (NHRI-EX106-10208PI, MOST 104-2314-B-182-027-MY3,BMRP888) (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 81. Wen FH, Chen JS, Chou WC, Chang WC, Shen WC, Hsieh Chia-Hsun, Tang ST* “Family Caregivers' Subjective Caregiving Burden, Quality of Life, and Depressive Symptoms Are Associated With Terminally Ill Cancer Patients' Distinct Patterns of Conjoint Symptom Distress and Functional Impairment in Their Last Six Months of Life.” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2019 Jan;57(1):64-72. doi: 10.1016/j.jpainsymman.2018.09.009. Epub 2018 Sep 27. PubMed PMID: 30267845. (NHRI-EX107-10704PI, MOST 104-2314-B-182-027-MY3,BMRP888) (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 82. Wen FH, Chen JS, Chou WC, Chang WC, Hsieh Chia-Hsun, Tang ST* ” Factors Predisposing Terminally Ill Cancer Patients' Preferences for Distinct Patterns/States of Life-Sustaining Treatments Over Their Last Six Months.” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2019 Feb;57(2):190-198.e2. doi: 10.1016/j.jpainsymman.2018.11.008. Epub 2018 Nov 15. PubMed PMID: 30447386. (NHRI-EX107-10704PI, MOST 104-2314-B-182-027-MY3,BMRP888) (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 83. Wang HY, Lu JJ, Chang CY, Chou WP, Hsieh Jason Chia-Hsun, Lin CR, Wu MH* “Development of a high sensitivity TaqMan-based PCR assay for the specific detection of Mycobacterium tuberculosis complex in both pulmonary and extrapulmonary specimens. “ Scientific Reports 2019 Jan 14;9(1):113. doi: 10.1038/s41598-018-33804-1. PubMed PMID: 30643154; PubMed Central PMCID: PMC6331544. [SCRPD2G0061, CMRPD2G0062] (2022 SCIE, IF: 4.6, MULTIDISCIPLINARY SCIENCES: 22/73 = 30.14%)
 84. Siew Tzuh Tang, Jen-Shi Chen, Fur-Hsing Wen, Wen-Chi Chou, John Wen-Cheng Chang, Chia-Hsun Hsieh , Chen Hsiu Chen* “Advance Care Planning Improves Psychological Symptoms But Not Quality of Life and Preferred End-of-Life Care of Patients With Cancer” Journal of the National Comprehensive Cancer Network. 2019 Apr 1;17(4):311-320. doi: 10.6004/jnccn.2018.7106. [NHRI-EX106-10208PI;MOST 105-2314-B-182-040-MY3;BMRP888] (2022 SCIE, IF: 13.4, ONCOLOGY: 19/241 = 7.88%)
 85. Fur-Hsing Wen, , Jen-Shi Chen, Wen-Chi Chou, Wen-Cheng Chang, Chia-Hsun Hsieh, Siew Tzuh Tang * “Extent and Determinants of Terminally Ill Cancer Patients' Concordance between Preferred and Received Life-Sustaining Treatment States: An Advance Care Planning Randomized Trial in Taiwan.” JOURNAL OF

- PAIN AND SYMPTOM MANAGEMENT. 2019 Apr 17. pii: S0885-3924(19)30178-2. doi: 10.1016/j.jpainsymman.2019.04.010. [Epub ahead of print] (NHRI-EX106-10208PI;MOST 105-2314-B-182-040-MY3;BMRP888) (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
86. Jen-Shi Chen, Fur-Hsing Wen, Wen-Chi Chou, Chia-Hsun Hsieh, Wen-Cheng Chang, Siew Tzuh Tang*
 “Terminally Ill Cancer Patients' Distinct Symptom-Functional Patterns/States Are Differentially Associated with Their Accurate Prognostic Awareness in the Last Six Months of Life.” JOURNAL OF PALLIATIVE MEDICINE . 2019 Jul;22(7):782-789. doi: 10.1089/jpm.2018.0538. Epub 2019 Mar 19.[NHRI-EX107-10704PI, MOST 104-2314-B-182-027-MY3, BMRP888] (2022 SCIE IF: 2.8, HEALTH CARE SCIENCES & SERVICES 56/105 = 53.33%)
 87. Pei-Hung Chang, Min-Hsien Wu, Sen-Yu Liu, Hung-Ming Wang, Wen-Kuan Huang , Chun-Ta Liao, Tzu-Chen Yen, Shu-Hang Ng, Jen-Shi Chen, Yung-Chang Lin, Hung-Chih Lin, and Jason Chia-Hsun Hsieh*(通訊作者) “The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing.” Cancers (Basel).2019 Apr 15;11(4). pii: E540. doi: 10.3390/cancers11040540. [107-TDU-B-212-114023(PMRPG3H0071), CMRPG3G0591-3,CORPG3F0731, CMRPG3E1631-33,MOST-107-2628-B-182A-001- CMRPG2G0681-3, CMRPG2D0171, CMRPG3G1131-1133, CMRPG3H0871-73, MOST-107-2314-B-182-053, MOST-104-2314-B-182-031-MY3,CMRPG3D1063, CMRPG3D1073,MOST104-2314-B-182A-073-MY3] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
 88. Hung-Ming Wang, Min-Hsien Wu, Pei-Hung Chang(共同第一作者), Hung-Chi Lin, Chun-Ta Liao, Sheng-Min Wu, Tsung-Min Hung, Chine-Yu Lin, Tung-Chieh Chang, Yen Tzu-Tsen, Jason Chia-Hsun Hsieh*(通訊作者) “The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer.” HEAD AND NECK- JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 2019 Aug;41(8):2676-2687. doi: 10.1002/hed.25744. Epub 2019 Mar 22. [107-TDU-B-212-114023 (PMRPG3H0071), CMRPG3G0591-3, CORPG3F0731, CMRPG3E1631-33, CMRPG2G0681-3, MOST-107-2628-B-182A-001, CMRPG2G0683 , CMRPG3G1131-1133, CMRPG3H0871-73, MOST-107-2314-B-182-053, MOST-104-2314-B-182-031-MY3, CMRPG3D1063, CMRPG3D1073, MOST104-2314-B-182A-073-MY3] (2022 SCIE, IF: 2.9, OTORHINOLARYNGOLOGY: 8/43 = 18.6%)
 89. Chia-Jung Liao, Chia-Hsun Hsieh(共同第一作者), Feng-Chun Hung, Hung-Ming Wang, Wen-Pin Chou, Min-Hsien Wu* “The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell (CTC) Isolation and Purification Process: A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients.” Cancers (Basel). 2019 Jun 6;11(6). pii: E783. doi: 10.3390/cancers11060783. (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
 90. Tzu-Keng Chiu, Yang Zhaob, Deyong Chen, Chia-Hsun Hsieh, Ke Wangb,Wen-Pin Chou, Chia-Jung Liao, Hsin-Yao Wang, Beiyuan Fan, Junbo Wang*, Jian Chen*, Min-Hsien Wu “A low-sample-loss microfluidic

- system for the quantification of size-independent cellular electrical property—Its demonstration for the identification and characterization of circulating tumour cells (CTCs). “ SENSORS AND ACTUATORS B-CHEMICAL, (2017)246, 29–37. doi:10.1016/j.snb.2017.02.048 [National Basic Research Program of China (973 Program, GrantNo. 2014CB744600), the National Natural Science Foundation of China (61431019, 61671430), the Natural Science Foundation of Beijing (4152056), the Instrument Development Program of the Chinese Academy of Sciences, the Beijing NOVA Program of Science and Technology, Chinese Academy of Sciences Key Project Targeting Cutting-Edge Scientific Problems (QYZDB-SSW-JSC011),CMRPD2C0101- 02,CMRPD2E0011 -12, CMRPD2D0041-43] (2022 SCIE: 8.4, INSTRUMENT & INSTRUMENTATION: 1/63 = 1.59%)
91. Wen-Pin Chou, Hung-Ming Wang, Jyun-Huan Chang, Tzu-Keng Chiu, Chia-Hsun Hsieh, Chia-Jung Liao*, Min-Hsien Wu “The utilization of optically-induced-dielectrophoresis (ODEP)-based virtual cell filters in a microfluidic system for continuous isolation and purification of circulating tumour cells (CTCs) based on their size characteristics.” SENSORS AND ACTUATORS B-CHEMICAL, (2017)241, 245–254. doi:10.1016/j.snb.2016.10.075 [CMRPG3F0131, CMRPD2C0101-02, CMRPD2D0041-43] (2022 SCIE: 8.4, INSTRUMENT & INSTRUMENTATION: 1/63 = 1.59%)
 92. Chen YL, Huang WC, Lin FM, Hsieh HB, Hsieh Chia-Hsun, Hsieh RK, Chen KW, Yen MH, Lee J, Su S, Marfatia T, Chang SE, Sundar P, Patterson B, Watson D, Mei R, Javey M.* “Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.” CANCER IMMUNOLOGY IMMUNOTHERAPY. 2019 Jul;68(7):1087-1094. doi: 10.1007/s00262-019-02344-6. Epub 2019 May 14. (2022 SCIE, IF: 5.8; Oncology: 59/241 = 24.48%)
 93. Jason Chia-Hsun Hsieh*(第一作者與通訊作者), Hung-Ming Wang, Min-Hsien Wu, Kai-Ping Chang, Pei-Hung Chang, Chun-Ta Liao, Chi-Ting Liao “Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy.” HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 2019 Oct;41 Suppl 1:19-45. doi: 10.1002/hed.25932.[MOST-107-2628-B-182A-001-, MOST107-2314-B-182-053, MOST-104-2314-B-182-031-MY3, MOST-104-2314-B-182A-073-MY3, CMRPG3G0591-93, CORPG3F0771, CORPG3F0791, CMRPG3E1631-33, CMRPG2G0681-83, CMRPG2J0061, CMRPG3G1131-33, CMRPG3H0871-73, CMRPG3D1061-1063, CMRPG3D1071-1073, PMRPG3H0071-74 (2022 SCIE, IF: 2.9, OTORHINOLARYNGOLOGY: 8/43 = 18.6%)
 94. Chien-Yu Lin, Kang-Hsing Fan, Li-Yu Lee, Chuen Hsueh, Lan Yan Yang, Shu-Hang Ng, Hung-Ming Wang, Chia-Hsun Hsieh, Chih-Hung Lin, Chung-Kan Tsao, Chung-Jan Kang, Tuan-Jen Fang, Li-Ang Lee , Shiang-Fu Huang, Kai-Ping Chang, Tzu-Chen Yen, Ze Yun Tay, Yu-Wen Wen, Shu Ru Lee, Chun-Ta Liao* “Precision Adjuvant Therapy Based on Detailed Pathologic Risk Factors for Resected Oral Cavity Squamous Cell Carcinoma: Long-Term Outcome Comparison of CGMH and NCCN Guidelines” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2020 Apr

- 1;106(5):916-925. doi: 10.1016/j.ijrobp.2019.08.058. Epub 2019 Sep 6. (2022 SCIE, IF: 7.0, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING: 12/135 = 8.89%)
95. Jia-Long Hong, Chia-Ming Yang, Po-Yu Chu, Wen-Pin Choug, Chia-Jung Liao, Chia-Hsun Hsieh, Min-Hsien Wu, Ping-Hei Chen* “The effect of operating conditions on the optically induced electrokinetic (OEK)-based manipulation of magnetic microbeads in a microfluidic system “ SENSORS AND ACTUATORS B-CHEMICAL Volume 296, 1 October 2019, 126610 [MOST 105-2221-E-182-028-MY3, MOST 104-2628-E-182-002-MY3, MOST 107-2221-E-182-033-MY3, CMRPD2E0011-13, CMRPD2G0061-62, CMRPD2D0041-43.] (2022 SCIE: 8.4, INSTRUMENT & INSTRUMENTATION: 1/63 = 1.59%)
 96. Tzu-Yao Liao, Chuang-Chi Liaw, Hui-Ching Hsu, Chia-Hsun Hsieh, John Wen-Cheng Chang And Yu-Hsiang Juan* “Extrahepatic Portal Venous Obstruction With Hepatic Enzyme Elevation Resembling Hepatitis in Patients With Cancer.” IN VIVO. 2019 Sep-Oct;33(5):1697-1702. doi: 10.21873/in vivo.11658. (2022 SCIE IF: 2.3, MEDICINE, RESEARCH & EXPERIMENTAL: 103/136 = 75.74%)
 97. Wen FH, Chou WC, Chen JS, Chang WC, Hsieh Chia-Hsun, Shen WC, Tang ST* “Associations of preloss and postloss factors with severe depressive symptoms and quality of life over the first 2 years of bereavement for family caregivers of terminally ill cancer patients.” PSYCHO-ONCOLOGY. 2019 Nov;28(11):2157-2165. doi: 10.1002/pon.5201. Epub 2019 Aug 30. (2022 SCIE, IF: 3.6, SOCIAL SCIENCES, BIOMEDICAL: 11/45 = 24.44%)
 98. Chih-Kai Wong, Sheng-Chieh Chan, Shu-Hang Ng, Chia-Hsun Hsieh, Nai-Ming Cheng, Tzu-Chen Yen, Chun-Ta Liao* “Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma.” MEDICINE. 2019 Aug;98(33):e16608. doi: 10.1097/MD.00000000000016608 (2022 SCIE, IF: 1.6, MEDICINE, GENERAL & INTERNAL: 118/167 = 70.66%)
 99. Li-Yu Lee, Dante De Paz, Chien-Yu Lin, Kang-Hsing Fan, Hung-Ming Wang, Chia-Hsun Hsieh, Li-Ang Lee, Tzu-Chen Yen, Chun-Ta Liao, Ching-Hua Yeh, Chung-Jan Kan* “Prognostic impact of extratumoral perineural invasion in patients with oral cavity squamous cell carcinoma.” Cancer Medicine. 2019 Oct;8(14):6185-6194. doi: 10.1002/cam4.2392. Epub 2019 Jul 10. [CMRPG3I0011, CMRPG3I0012, CMRPG3I0013.] (2022 SCIE, IF: 4.0, ONCOLOGY: 96/241 = 39.83%)
 100. Chun-Ta Liao, Chia-Hsun Hsieh, Wen-Lang Fan, Shu-Hang Ng(共同第一作者), Nai-Ming Cheng, Li-Yu Lee, Chuen Hsueh, Chien-Yu Lin, Kang-Hsing Fan, Hung-Ming Wang, Chih-Hung Lin, Chung-Kan Tsao, Chung-Jan Kang, Tuan-Jen Fang, Shiang-Fu Huang, Kai-Ping Chang, Li-Ang Lee, Ku-Hao Fang, Yu-Chien Wang, Lan-Yan Yang, Tzu-Chen Yen* “A combined analysis of maximum standardized uptake value on FDG-PET, genetic markers, and clinicopathological risk factors in the prognostic stratification of patients with resected oral cavity squamous cell carcinoma.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2020 Jan;47(1):84-93. doi: 10.1007/s00259-019-04453-x. Epub 2019 Aug

6. [CIRPG1E0012, PMRPG3H0071] (2022 SCIE, IF: 9.1, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING: 7/135 = 5.19%) .
101. Siew Tzuh Tang, Siew Tzuh Tang, Wen-Chi Chou, Wen-Cheng Chang, Jen-Shi Chen, Chia-Hsun Hsieh, Fur-Hsing Wen, Shih-Chi Chung* “Courses of Change in Good Emotional Preparedness for Death and Accurate Prognostic Awareness and Their Associations With Psychological Distress and Quality of Life in Terminally Ill Cancer Patients' Last Year of Life.” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2019 Oct;58(4):623-631.e1. doi: 10.1016/j.jpainsymman.2019.06.022. Epub 2019 Jul 2.[MOST 104-2314-B-182-027-MY,NHRI-EX108-10704PI, BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
102. Chun-Ta Liao, Li-Yu Lee, Chuen Hsueh, Chien-Yu Lin, Kang-Hsing Fan, Hung-Ming Wang, Chia-Hsun Hsieh, Shu-Hang Ng, Chih-Hung Lin, Chung-Kan Tsao, Chung-Jan Kang, Tuan-Jen Fang, Shiang-Fu Huang, Kai-Ping Chang, Li-Ang Lee, Ku-Hao Fang, Yu-Chien Wang, Wan-Ni Lin, Li-Jen Hsin, Lan Yan Yang, Tzu-Chen Yen* “Tumor Depth of Invasion (Tumor > 4 cm/Depth > 10 mm and Depth > 20 mm) and Through Cortex/Skin Invasion are Both Valid Criteria for Classifying Tumors as pT4a in AJCC 2018 Oral Cavity Cancer Staging System.” ANNALS OF SURGICAL ONCOLOGY. 2019 Oct;26(11):3663-3672. doi: 10.1245/s10434-019-07576-5. Epub 2019 Jul 1.[MOHW107-TDU-B-212- 123005] (2022 SCIE:3.7, SURGERY:35/212 = 16.51%)
103. Fur-Hsing Wen, Jen-Shi Chen, Wen-Cheng Chang, Wen-Chi Chou, Chia-Hsun Hsieh, Siew Tzuh Tang* “Accurate prognostic awareness and preference states influence the concordance between terminally ill cancer patients' states of preferred and received life-sustaining treatments in the last 6 months of life” JOURNAL OF PALLIATIVE MEDICINE. 2019 Sep;33(8):1069-1079. doi: 10.1177/0269216319853488. Epub 2019 Jun 12.[NHRI-EX108-10704PI, MOST 104-2314-B-182-027-MY3, BMRP888]. (2022 SCIE IF: 2.8, HEALTH CARE SCIENCES & SERVICES 56/105 = 53.33%)
104. Lin CH, Hung TM, Chang YC, Hsieh Jason Chia-Hsun, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK* ”Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy.” Cancers (Basel). 2020 Mar 6;12(3). pii: E607. doi: 10.3390/cancers12030607. (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
105. Chen Hsiu Chen, Wen-Chi Chou, Jen-Shi Chen, Wen-Cheng Chang, Chia-Hsun Hsieh, Fur-Hsing Wen, Siew Tzuh Tang* “An Individualized, Interactive, and Advance Care Planning Intervention Promotes Transitions in Prognostic Awareness States Among Terminally Ill Cancer Patients in Their Last Six Months- A Secondary Analysis of a Randomized Controlled Trial.” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT.. 2020 Jul;60(1):60-69.e6. doi: 10.1016/j.jpainsymman.2020.01.012. Epub 2020 Feb 20. (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
106. Chia-Hsun Hsieh(第一作者), Chien-Yu Lin, Cheng-Lung Hsu, Kang-Hsing Fan, Shiang-Fu Huang, Chun-

- Ta Liao, Li-Yu Lee, Shu-Kung Ng, Tzu-Chen Yen, Joseph Tung-Chieh Chang, Jr-Rung Lin & Hung-Ming Wang* “Incorporation of Astragalus polysaccharides injection during concurrent chemoradiotherapy in advanced pharyngeal or laryngeal squamous cell carcinoma: preliminary experience of a phase II double-blind, randomized trial.” JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2020 Jan;146(1):33-41. doi: 10.1007/s00432-019-03033-8. Epub 2019 Nov 14. (2022 SCIE, IF: 3.6, ONCOLOGY: 118/241 = 48.96%)
107. Ching-Yang Wu, Chia-Lin Lee, Ching-Feng Wu, Jui-Ying Fu, Cheng-Ta Yang, Chi-Tsung Wen, Yun-Hen Liu, Hui-Ping Liu and Jason Chia-Hsun Hsieh* (通訊作者) “Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial.” Diagnostics. 2020 Mar 6;10(3). pii: E144. doi: 10.3390/diagnostics10030144[CMRPG3H1681 CMRPG3G0591-3, CORPG3G0791, CORPG3G0771,MOST-108-2628-B-182A-001] (2022 SCIE, IF:3.6, MEDICINE ,GENARAL& INTERNAL:63/167 = 37.72%)
108. Jason Chia-Hsun Hsieh(第一作者), Guan-Yu Chen, David Da-Wei Jhou, Wen-Chi Chou, Chun-Nan Yeh, Tsann-Long Hwang, Hung-Chi Lin, Hui-Chun Chu, Hung-Ming Wang, Tzu-Chen Yen, Jen-Shi Chen & Min-Hsien Wu* ” The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors” Scientific Reports. 2019 Dec 27;9(1):19917. doi: 10.1038/s41598-019-56539-z. (2022 SCIE, IF: 4.6, MULTIDISCIPLINARY SCIENCES: 22/73 = 30.14%)
109. Shiue-Luen Chen, Chong-You Chen, Jason Chia-Hsun Hsieh(共同第一作者), Zih-Yu Yu, Sheng-Jen Cheng, Kuan Yu Hsieh, Jia-Wei Yang, Priyank V Kumar, Shien-Fong Lin and Guan-Yu Chen* “Graphene Oxide-Based Biosensors for Liquid Biopsies in Cancer Diagnosis.” Nanomaterials. 2019 Dec 3;9(12). pii: E1725. doi: 10.3390/nano9121725.[108W204,108W211, MOST 107-2622-E-009-023-CC1, MOST-107-EPA-F-007-002, MOST-108-2636-E-009-007-, , MOST 108-2633-B-009-001.] (2022 SCIE, IF: 5.3, PHYSICS, APPLIED: 38/159 = 23.89%)
110. Chun-Hui Lee, Jason Chia-Hsun Hsieh(共同第一作者), Tyler Min-Hsien Wu, Ting-Shiuan Yeh, Hung-Ming Wang, Yung-Chan Lin, Jen-Shi Chen, Chia-Lin Lee, Wen-Kuan Huang, Tsung-Min Hung, Tzu-Tsen Yen, Sheng-Chieh Chan, Wen-Chi Chou, Feng-Che Kuan, Ching-Chih Hu & Pei-Hung Chang* “Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer” BMC Cancer. 2019 Dec 2;19(1):1167. doi: 10.1186/s12885-019-6370-1.[CMRPG2D0171, CMRPG2D0172, CMRPG2G0681, CMRPG2G0682, CMRPG2G0683, CMRPG2Jzs0061-3 to PH Chang; CMRPG2D0173 to Chun-Hui Lee, PMRPG3H0071, CMRPG3G0593, CORPG3G0791, CORPG3G0771, CMRPG3E1631–33, MOST-108-2628-B-182A-001 to CH Hsieh; CMRPG3G1131–1133, CMRPG3H0871–73, MOST-107-2314-B-182-053, MOST-104-2314-B-182-031-MY3] (2022 SCIE, IF: 3.8, ONCOLOGY: 109/241 = 45.23%)
111. Sheng-Jen Cheng, Kuan Yu Hsieh, Shiue-Luen Chen, Chong-You Chen, Chien-Yu Huang, Hung-I Tsou,

- Priyank V. Kumar, Jason Chia-Hsun Hsieh* and Guan-Yu Chen* (共同通訊作者) “Microfluidics and Nanomaterial-based Technologies for Circulating Tumor Cell Isolation and Detection.” *SENSORS*. 2020 Apr; 20(7): 1875. Published online 2020 Mar 27. doi: 10.3390/s20071875 [MOST-108-2218-E-080-001-, MOST-109-2636-E-009-007, NHRI-EX109-10714EC, 109AS-24.2.1-AD-U2, MOST-108-2628-B-182A-001, MOST-109-2628-B-182A-001,CMRPG3G0593] (2022 SCIE: 3.9, INSTRUMENT & INSTRUMENTATION: 19/63 = 30.15%)
112. Chiao-En Wu, Wen-Chi Chou, Chia-Hsun Hsieh, John Wen-Cheng Chang, Cheng-Yu Lin , Chun-Nan Yeh , Jen-Shi Chen* “Prognostic and Predictive Factors for Taiwanese Patients With Advanced Biliary Tract Cancer Undergoing Frontline Chemotherapy With Gemcitabine and Cisplatin: A Real-World Experience” *BMC Cancer*. 2020 May 14;20(1):422. doi: 10.1186/s12885-020-06914-1.PMID: 32410631 [CRRPG3F0031 ~ 3, CMRPG3I023, CMRPG3I0241, CORPG3J0251, NMRPG3F6021~ 2,NMRPG3H6211 ~ 2 CMRPG3I0451, CMRPG3J0971, NMRPG3J0011,105–2314-B-182A-041-MY2, 107–2314-B-182A-134-MY3, 108–2314-B-182A-007] (2022 SCIE, IF: 3.8, ONCOLOGY: 109/241 = 45.23%)
113. Siew Tzuh Tang, Wen-Chi Chou, Chia-Hsun Hsieh, Wen-Cheng Chang, Jen-Shi Chen, Fur-Hsing Wen* “Terminally Ill Cancer Patients' Emotional Preparedness for Death Is Distinct From Their Accurate Prognostic Awareness .” *JOURNAL OF PAIN AND SYMPTOM MANAGEMENT*. 2020 Oct;60(4):774-781.e1. doi: 10.1016/j.jpainsymman.2020.04.021. Epub 2020 Apr 30. [MOST104-2314-B-182-027-MY, NHRI-EX109-10704PI, BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
114. Courtney J Ensslin, Pei-Han Kao, Ming-Ying Wu, Yao-Yu Chang, Tseng-Tong Kuo, Chia-Hsun Hsieh, Sen-Yung Hsieh, Chih-Hsun Yang, Lloyd S Miller* “Psoriasiform Drug Eruption Secondary to Sorafenib: Case Series and Review of the Literature” *CUTIS*. 2019 Sep;104(3):E11-E15. (2021 SCIE IF: 1.6, DERMATOLOGY: 55/70 = 78.57%)
115. Po-Yu Chu, Chia-Hsun Hsieh(共同第一作者), Chien-Ru Lin, Min-Hsien Wu* "The effect of optically induced dielectrophoresis (ODEP)-based cell manipulation in a microfluidic system on the properties of biological cells" *Biosensors-Basel*. 2020 Jun; 10(6): 65.Published online 2020 Jun 16. doi: 10.3390/bios10060065 [MOST107–2221-E-182–033-MY3,CMRPD2G0061–62, CMRPD2H0121–23,CMRPD2J0031–32] (2022 SCIE, IF: 5.4, CHEMISTRY,ANALYTICAL: 14/86 = 16.28%)
116. Po-Yu Chu, Chia-Hsun Hsieh(共同第一作者), Min-Hsien Wu* “The combination of immunomagnetic bead-based cell isolation and optically induced dielectrophoresis (ODEP)-based microfluidic device for the negative selection-based isolation of circulating tumor cells (CTCs)” *Frontiers in Bioengineering and Biotechnology* 2020 Aug 6;8:921. doi: 10.3389/fbioe.2020.00921. eCollection 2020. [107-2221-E-182-033-MY3, CMRPD2G0061-62, CMRPD2H0121-23, and CMRPD2J0031-32] (2022 SCIE, IF: 5.7, MULTISCIPLINARY SCIENCES: 16/73 = 21.23%)
117. Chung-Jan Kang, Hung-Ming Wang, Chien-Yu Lin, Kang-Hsing Fan, Li-Yu Lee, Chia-Hsun Hsieh, Chi-

- Che Huang, Chun-Ta Liao, Tzu-Chen Yen* “Next Generation Sequencing (NGS) for Prognostic Stratification in Oral Cancer Harboring Lymph Node Metastasis without Extranodal Extension”
International Journal of Head and Neck Science 2019;3(3) 159 – 172. Doi:
10.6696/IJHNS.201909_3(3).0005
118. Yi-Ju Tseng, Hsin-Yao Wang, Ting-Wei Lin, Jang-Jih Lu, Chia-Hsun Hsieh*(通訊作者), Chun-Ta Liao
“Development of a Machine Learning Model for Survival Risk Stratification of Patients With Advanced Oral Cancer” JAMA Network Open. 2020 Aug 3;3(8):e2011768. doi:
10.1001/jamanetworkopen.2020.11768. [CMRPD3I0011, CMRPG3G0593, MOST-109-2636-E-182-001, MOST-108-2628-B-182A-001, MOST-108-2314-B-182A113-MY3 EMRPDI0431, EMRPDI0501, EMRPDI0481] (2022 SCIE, IF: 13.8, MEDICINE, GENERAL & INTERNAL: 15/167 = 8.98%)
119. Wang HY, Lin TW, Chiu SY, Lin WY, Huang SB, Jason Chia-Hsun Hsieh, Chen HC, Lu JJ, Wu MH*
“Novel Toilet Paper-Based Point-Of-Care Test for the Rapid Detection of Fecal Occult Blood: Instrument Validation Study” JOURNAL OF MEDICAL INTERNET RESEARCH. 2020 Aug 7;22(8):e20261. doi:
10.2196/20261. [SCRPD2I0011, CMRPD2J0031-33] (2022 SCIE IF: 7.4, HEALTH CARE SCIENCES & SERVICES 3/105 = 2.86%)
120. Pan YR, Wu CE, Wang YC, Yeh YC, Lu ML, Hung YP, Chao Y, Yeh DW, Lin CH, Jason Chia-Hsun Hsieh, Chen MH, Yeh CN* “Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response” Clinical & Translational Immunology 2020 Jun 30;9(7):e1145. doi: 10.1002/cti.2.1145. eCollection 2020. (2022 SCIE IF: 5.8, IMMUNOLOGY 51/161 = 31.68%)
121. Tang ST, Chang WC, Chou WC, Hsieh Chia-Hsun, Chen JS, Wen FH* “Family Caregivers' Emotional Preparedness for Death Is Distinct from Their Cognitive Prognostic Awareness for Cancer Patients” JOURNAL OF PALLIATIVE MEDICINE 2021 Mar;24(3):405-412. doi: 10.1089/jpm.2020.0264. Epub 2020 Aug 13. PMID: 32790487. (2022 SCIE IF: 2.8, HEALTH CARE SCIENCES & SERVICES 56/105 = 53.33%)
122. Yang CY, Liu CR, Chang IY, OuYang CN, Hsieh Chia-Hsun, Huang YL, Wang CI, Jan FW, Wang WL, Tsai TL, Liu H, Tseng CP, Chang YS, Wu CC, Chang KP. “Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts” Cancers (Basel). 2020 Jun 29;12(7):1726. doi: 10.3390/cancers12071726. Cancers (Basel). 2020. PMID: 32610557 [MOST 108-2314-B-182A-108-MY3, MOST 107-2314-B-182-075-MY3, MOST 108-2320-B-182-030-MY3, CMRPG3H0852, CMRPG3J1251, CORPD1J0101-3] (2022 SCIE IF: 5.2, ONCOLOGY: 72/241 = 29.88%)
123. Hung TM, Fan KH, Kang CJ, Huang SF, Lin CY, Ho AT, Wang HM, Jason Chia-Hsun Hsieh, Cheng AJ,

- Ng SH, Chang JT* “Lymph node-to-primary tumor standardized uptake value ratio on PET predicts distant metastasis in nasopharyngeal carcinoma” ORAL ONCOLOGY. 2020 Nov;110:104756. doi: 10.1016/j.oraloncology.2020.104756. Epub 2020 Jul 8. PMID: 32652479. [107-2314-B-182A-062-MY3, CMRPG3G1411-3] (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
124. Chen PJ, Yap WK, Chang YC, Tseng CK, Chao YK, Jason Chia-Hsun Hsieh, Pai PC, Lee CH, Yang CK, Ho AT, Hung TM* “Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer” BMC Cancer .2020 Jun 10;20(1):545. doi: 10.1186/s12885-020-07044-4. (2022 SCIE, IF: 3.8, ONCOLOGY: 109/241 = 45.23%)
125. Fur-Hsing Wen, Chen Hsiu Chen, Wen-Chi Chou, Jen-Shi Chen, Wen-Cheng Chang, Chia-Hsun Hsieh, Siew Tzuh Tang “Evaluating if an Advance Care Planning Intervention Promotes Do-Not-Resuscitate Orders by Facilitating Accurate Prognostic Awareness” Journal of the National Comprehensive Cancer Network . 2020 Dec 2;18(12):1658-1666. doi: 10.6004/jnccn.2020.7601. Print 2020 Dec. PMID: 33285517 [NHRI-EX106-10208PI NHRI-EX109-10704PI MOST 105-2314-B-182-040-MY3, BMRP888] (2022 SCIE, IF: 13.4, ONCOLOGY: 19/241 = 7.88%)
126. Siew Tzuh Tang, Chia-Hsun Hsieh, Wen-Chi Chou, Wen-Cheng Chang, Jen-Shi Chen, Fur-Hsing Wen “Course of Changes in Emotional Preparedness for Death and Its Associations With Caregiving Outcomes for Family Caregivers of Terminally Ill Cancer Patients Over Their Last Year of Life” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT 2021 May;61(5):974-982. doi: 10.1016/j.jpainsymman.2020.09.033. Epub 2020 Sep 28. PMID: 32991973. [MOST 104-2314-B-182-027-MY3, NHRI-EX108-10704PI, BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
127. Wen FH, Chou WC, Chia-Hsun Hsieh, Chen JS, Chang WC, Tang ST “ Conjoint cognitive and emotional death-preparedness states and their changes within cancer patients' last 6 months “ PSYCHO-ONCOLOGY.2021 May;30(5):691-698. doi: 10.1002/pon.5614. Epub 2021 Jan 4. PMID: 33345399. [MOST 104-2314-B-182-027-MY3, NHRI-EX109-10704PI, BMRP888] (2022 SCIE, IF: 3.6, SOCIAL SCIENCES, BIOMEDICAL: 11/45 = 24.44%)
128. Tsai HI, Chou TC, Yu MC, Yeh CN, Peng MT, Chia-Hsun Hsieh, Su PJ, Wu CE, Kuo YC, Chiu CC, Lee CW. “ Purely laparoscopic feeding jejunostomy: a procedure which deserves more attention ” BMC Surgery. 2021 Jan 13;21(1):37. doi: 10.1186/s12893-021-01050-4. PMID: 33441134; PMCID: PMC7805100 [CMRPG3J1691, CMRPG3I0301] (2022 SCIE, IF: 1.9, SURGERY: 120/212 = 56.60%)
129. Fur-Hsing Wen, Wen-Chi Chou, Chia-Hsun Hsieh, Jen-Shi Chen, Wen-Cheng Chang, Siew Tzuh Tang “ Distinct Death-Preparedness States by Combining Cognitive and Emotional Preparedness for Death and Their Evolution for Family Caregivers of Terminally Ill Cancer Patients Over Their Last 6 Months of Life ” JOURNAL OF PAIN AND SYMPTOM MANAGEMENT . 2021 Sep;62(3):503-511. doi: 10.1016/j.jpainsymman.2021.01.131. Epub 2021 Feb 6. PMID: 33561490. [MOST 104-2314-B-182-027-MY3, NHRI-EX109-10704PI, BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)

130. Selvaraj Rajesh Kumar, Ya-Hui Hsu, Truong Thi Tuong Vi, Jong-Hwei Su Pang, Yao-Chang Lee, Chia-Hsun Hsieh*(通訊作者), and Shingjiang Jessie Lue* “Graphene Oxide-Induced Protein Conformational Change in Nasopharyngeal Carcinoma Cells A Joint Research on Cytotoxicity and Photon Therapy” *MATERIALS* 2021, 14(6), 1396; Published: 13 March 2021 [CMRPD2K0141, CMRPD2F0053, MOST 109-2811-E-182-507-MY2] (2022 SCIE IF: 3.4, METALLURGY & METALLURGICAL ENGINEERING: 20/78 = 25.64%)
131. Tran, Thi Tuong, Selvaraj Rajesh Kumar, Chi Hieu Nguyen, Jing Wen Lee, Hui-An Tsai, Chia-Hsun Hsieh, and Shingjiang Jessie Lue “High-Permeability Graphene Oxide and Poly(Vinyl Pyrrolidone) Blended Poly(Vinylidene Fluoride) Membranes: Roles of Additives and Their Cumulative Effects” *JOURNAL OF MEMBRANE SCIENCE* 2021, 619, 118773. doi:10.1016/j.memsci.2020.118773. Online ahead of print. [MOST 108-2221-E-182-021-MY, CMRPG2G042] (2022 SCIE, IF: 9.5, POLYMER SCIENCE: 4/86 = 4.65%)
132. Oliveira, Thiago Bueno, Ricard Mesía, Agustin Falco, Jason Chia-Hsun Hsieh, Tomoya Yokota, Esma Saada-Bouazid, Sandra Schmitz, Olgun Elicin, Luca Giacomelli, and Paolo Bossi. “Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion.” *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY* 2021 Jan;157:103200. doi: 10.1016/j.critrevonc.2020.103200. Epub 2020 Dec 13. PMID: 33321152. (2022 SCIE, IF: 6.2, ONCOLOGY: 54/241 = 22.41%)
133. Fan KH, Yeh CH, Hung SP, Kang CJ, Huang SF, Chang KP, Wang HM, Jason Chia-Hsun Hsieh, Lin CY, Cheng AJ, Ng SH, Tung-Chieh Chang J “Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation” *RADIOTHERAPY AND ONCOLOGY* 2021 Mar;156:217-222. doi: 10.1016/j.radonc.2020.12.028. Epub 2020 Dec 30. PMID: 33385465. [MOST 107-2314-B-182A-062-MY, CMRPG3G1411] (2022 SCIE, IF: 5.7, Radiology, Nuclear Medicine & Medical Imaging 17/135 = 12.59%)
134. Lin CR, Wang HY, Lin TW, Lu JJ, Chia-Hsun Hsieh, Wu MH “Development of a two-step nucleic acid amplification test for accurate diagnosis of the Mycobacterium tuberculosis complex” *Scientific reports* 2021 Mar 11;11(1):5750. doi: 10.1038/s41598-021-85160-2. PMID: 33707640; PMCID: PMC7952592. [MOST 107-2221-E-182-033-MY3 CMRPD2G0061-62, CMRPD2H0121-23, and CMRPD2J0031-32] (2022 SCIE, IF: 4.6, MULTIDISCIPLINARY SCIENCES: 22/73 = 30.14%)
135. Peng, Hsin-Yin, Chia-Ming Yang, Yu-Ping Chen, Hui-Ling Liu, Tsung-Cheng Chen, Dorota G. Pijanowska, Po-Yu Chu, Chia-Hsun Hsieh, and Min-Hsien Wu “An Integrated Actuating and Sensing System for Light-Addressable Potentiometric Sensor (LAPS) and Light-Actuated AC Electroosmosis (LACE) Operation” *Biomicrofluidics* 2021 Apr 12;15(2):024109. doi: 10.1063/5.0040910. PMID: 33868536; PMCID: PMC8043754. [MOST 108-2628-E-182-002-MY3, MOST 108-2221-E-182-060-MY3, MOST 107-2221-E-182-033-MY3, CMRPD2K0021, CMRPD2I0012, CMRPD2G0061-62, CMRPD2H0121-23, CMRPD2J0031-32] (2022 SCIE, IF: 3.2, PHYSICS, FLUIDS & PLASMAS: 11/34 = 32.35%)
136. Wu-Chou, Yah-Huei, Chia-Hsun Hsieh, Chun-Ta Liao, Yin-Ting Lin, Wen-Lang Fan, and Cheng-Han Yang

- “NOTCH1 Mutations as Prognostic Marker in Oral Squamous Cell Carcinoma” PATHOLOGY RESEARCH AND PRACTICE 2021 Jul;223:153474. doi: 10.1016/j.prp.2021.153474. Epub 2021 May 10. PMID: 33993060. (2022 SCIE, IF: 2.8, PATHOLOGY: 37/76 = 48.68%)
137. Tsai, Chi-Ying; Lee, Shu Ru; Lee, Li-Yu; Hsueh, Chuen; Lin, Chien-Yu; Fan, Kang-Hsing; Wang, Hung-Ming; Hsieh, Chia-Hsun; Ng, Shu-Hang; Yeh, Chih-Hua “Clinical outcomes of Taiwanese patients with resected squamous cell carcinoma of the upper and lower gum” ORAL ONCOLOGY 2021 Jul;118:105334. doi: 10.1016/j.oraloncology.2021.105334. Epub 2021 May 19. PMID: 34020150. [CMRPD1H0521, BMRPC5] (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
 138. Wu, Ching-Yang, Jui-Ying Fu, Ching-Feng Wu, Ming-Ju Hsieh, Yun-Hen Liu, Hui-Ping Liu, Jason Chia-Hsun Hsieh(通訊作者), and Yang-Teng Peng “Malignancy Prediction Capacity and Possible Prediction Model of Circulating Tumor Cells for Suspicious Pulmonary Lesions” Journal of Personalized Medicine 2021, 11(6), 444; Published: 21 May 2021 [CMRPG3H1681, CMRPG3J0531, CMRPG3K1791] (2022 SCIE IF: 3.508, HEALTH CARE SCIENCES & SERVICES 42/109 = 38.53%)
 139. Chiu, Sherry Yueh-Hsia, Chia-Hsun Hsieh, Jeng-Fu You(共同第一作者), Po-Yu Chu, Hsin-Yuan Hung, Pao-Hsien Chu, and Min-Hsien Wu “Enhancing Prediction Performance by Add-On Combining Circulating Tumor Cell Count, CD45neg EpCAMneg Cell Count on Colorectal Cancer, Advance, and Metastasis” Cancers (Basel). 2021 May 21;13(11):2521. doi: 10.3390/cancers13112521. PMID: 34063929; PMCID: PMC8196640. [MOST 107-2221-E-182-033-MY3; MOST 109-2314-B-182-038-MY3; MOST-109-2628-B-182A-001 CMRPVVK0091, CMRPVVL002, CMRPD2H0121-23, CMRPD2J0031-33 BMRP-B81] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
 140. Su TP, Huang JS, Chang PH, Lui KW, Jason Chia-Hsun Hsieh, Ng SH, Chan SC*. “Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer” BMC CANCER. 2021 Aug 10;21(1):908. doi: 10.1186/s12885-021-08649-z. PMID: 34376155; PMCID: PMC8353848. [CMRPG2C0481, CMRPG2C0482, CMRPG2C0483, CMRPG2E0341, and CMRPG2E0342] (2022 SCIE, IF: 3.8, ONCOLOGY: 109/241 = 45.23%)
 141. Kang CJ, Tsai CY, Lee LY, Lin CY, Yang LY, Cheng NM, Hsueh C, Fan KH, Wang HM, Chia-Hsun Hsieh, Ng SH, Yeh CH, Lin CH, Tsao CK, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Liao CT*. “Prognostic stratification of patients with AJCC 2018 pStage IVB oral cavity cancer: Should pT4b and pN3 disease be reclassified? ” ORAL ONCOLOGY. 2021 Aug;119:105371. doi: 10.1016/j.oraloncology.2021.105371. Epub 2021 Jun 24. PMID: 34174527. (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
 142. Lien, Ming-Yu, Ti-Hao Wang, Ching-Yun Hsieh, Ming-Hsui Tsai, Chun-Hung Hua, Fu-Ming Cheng, Wen-Hui Chung, Chih-Hsin Tang, and Jason Chia-Hsun Hsieh*(通訊作者). “Both Combined or Sequential Use with Immune Checkpoint Inhibitors on Cetuximab-Treated Patients with Recurrent or Metastatic Head and

- Neck Squamous Cell Carcinoma Improve the Overall Survival.” ORAL ONCOLOGY 119 (2021): 105380. <https://doi.org/10.1016/j.oraloncology.2021.105380>. [MOST-109-2628-B-182A-001, CMRPVVK0091, CMRPVVL0021, DMR-109-013] (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
143. Chu PY, Nguyen TNA, Wu AY, Huang PS, Huang KL, Liao CJ, Chia-Hsun Hsieh, Wu MH. The Utilization of Optically Induced Dielectrophoresis (ODEP)-Based Cell Manipulation in a Microfluidic System for the Purification and Sorting of Circulating Tumor Cells (CTCs) with Different Sizes. *Micromachines* (Basel). 2023 Nov 29;14(12):2170. doi: 10.3390/mi14122170. PMID: 38138338; PMCID: PMC10745986. [110-2221-E-182-004-MY3, 110-2811-E-182-507, 111-2811-E-182-009, CMRPD1M0561, CMRPD1M0562, CMRPD2M0291] (2022 SCIE, IF: 3.4, CHEMISTRY, ANALYTICAL: 30/86 = 34.88%)
144. Chun-Ta Liao, Lan-Yan Yang, Li-Yu Lee, Chien-Yu Lin, Hung-Ming Wang, Shu-Hang Ng, Tzu-Chen Yen, Wen-Lang Fan*, Jason Chia-Hsun Hsieh* (共同通訊作者) “Whole-exome sequencing identifies biosignatures that predict adverse survival outcomes in surgically treated patients with oral cavity squamous cell carcinoma” ORAL ONCOLOGY 2021 Nov;122:105547. doi: 10.1016/j.oraloncology.2021.105547. Epub 2021 Oct 23. PMID: 34700279. [MOST-109-2628-B-182A-001, MOST-109-2314-B-182-068, MOST-110-2314-B-182A-156, MOST-108-2314-B-182A-113 -MY3, CMRPG3G1131-33, CMRPG3H0871-73, CMRPVVK0091, CMRPVVL0021] (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
145. Jason Chia-Hsun Hsieh (第一作者), Pin-Chun Chiang, Tsung-Min Hung, Yin-Kai Chao, Yung-Chia Kuo, Chih-Tsung Wen, Po-Jung Su, Meng-Ting Peng, Huan-Wu Chen, Hui-Ling Liu, Hsien-Kun Chang, Min-Hsien Wu, Hung-Ming Wang* “Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence” *Cancer Medicine*. 2021 Dec;10(23):8300-8309. doi: 10.1002/cam4.4025. Epub 2021 Oct 27. PMID: 34706159; PMCID: PMC8633257. [CMRPVVK0091, CMRPVVL0021, CMRPG3G1133, CMRPG3H0872-73, MOST-108-2628-B-182A-001-, MOST-109-2628-B-182A-001-, 109-2314-B-182-068-] (2022 SCIE, IF: 4.0, ONCOLOGY: 96/241 = 39.83%)
146. Chang PH, Wang HM, Kuo YC, Lee LY, Liao CJ, Kuo HC, Hsu CL, Liao CT, Lin SH, Huang PW, Wu TM, Jason Chia-Hsun Hsieh* (通訊作者). “Circulating p16-Positive and p16-Negative Tumor Cells Serve as Independent Prognostic Indicators of Survival in Patients with Head and Neck Squamous Cell Carcinomas.” *Journal of Personalized Medicine*. 2021 Nov 7;11(11):1156. doi: 10.3390/jpm11111156. PMID: 34834510; PMCID: PMC8624430. [CMRPVVK0091, CMRPVVL0021, CMRPG2K0271, MOST 109-2628-B-182A-001] (2022 SCIE IF: 3.508, HEALTH CARE SCIENCES & SERVICES 42/109 = 38.53%)

147. Chou YC, Fan KH, Lin CY, Hung TM, Huang BS, Chang KP, Kang CJ, Huang SF, Chang PH, Hsu CL, Wang HM, Jason Chia-Hsun Hsieh, Cheng AJ, Chang JT*. “Intensity Modulated Proton Beam Therapy versus Volumetric Modulated Arc Therapy for Patients with Nasopharyngeal Cancer: A Propensity Score-Matched Study.” *Cancers (Basel)*. 2021 Jul 16;13(14):3555. doi: 10.3390/cancers13143555. PMID: 34298769; PMCID: PMC8307135.1 [CMRPG3K1571~2, MOST107-2314-B-182A-062-MY3.] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
148. Li HP, Huang CY, Lui KW, Chao YK, Yeh CN, Lee LY, Huang Y, Lin TL, Kuo YC, Huang MY, Lai YR, Yeh YM, Fan HC, Lin AC, Jason Chia-Hsun Hsieh, Chang KP, Lin CY, Wang HM, Chang YS, Hsu CL*. “Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment.” *Cancers (Basel)*. 2021 Jun 12;13(12):2954. doi: 10.3390/cancers13122954. PMID: 34204797; PMCID: PMC8231497. [CMRPG3H0161~3, CMRPG3H3J0331~2, CMRPG3H3J0301~2, CORPG3J0161~2, CMRPD1K0141~2, CMRPD1K0651, MOST107-2314-B-182-056-MY2, MOST-108-2311-B-182-002, EMRPD1L0281] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
149. Fan WL, Yang LY, Jason Chia-Hsun Hsieh, Lin TC, Lu MJ, Liao CT*. “Prognostic Genetic Biomarkers Based on Oncogenic Signaling Pathways for Outcome Prediction in Patients with Oral Cavity Squamous Cell Carcinoma.” *Cancers (Basel)*. 2021 May 30;13(11):2709. doi: 10.3390/cancers13112709. PMID: 34070941; PMCID: PMC8199274. [MOST-108-2314-B-182A-113 -MY3, MOST-109-2628-B-182A-001, CMRPG3G1131-33, CMRPG3H0871-73, CMRPG3D1061-63, CMRPG3D1071-73, CMRPG3G0593, CIRPG1E0012, CMRPVVK0091, CMRPVVL0021, CMRPG3J0501-02] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
150. Cheng NM, Kang CJ(共同第一), Tsai CY, Lee LY, Lin CY, Hsueh C, Fan KH, Wang HM, Jason Chia-Hsun Hsieh, Ng SH, Yeh CH, Lin CH, Tsao CK, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Liao CT*. “Improved prognostic stratification of patients with pN3b oral cavity cancer based on maximum standardized uptake value of metastatic nodes, lymph node ratio, and level of cervical nodal metastases.” *ORAL ONCOLOGY*. 2021 Dec;123:105593. doi: 10.1016/j.oraloncology.2021.105593. Epub 2021 Nov 9. PMID: 34768211. [MOST 106-2314-B-182A-025-MY3] (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
151. Chu PY, Jason Chia-Hsun Hsieh, Chen CY, Wu MH*. “Improvement of Background Solution for Optically Induced Dielectrophoresis-Based Cell Manipulation in a Microfluidic System.” *Frontiers in Bioengineering and Biotechnology*. 2021 Nov 22;9:759205. doi: 10.3389/fbioe.2021.759205. PMID: 34881232; PMCID: PMC8645848. [MOST 110-2221-E-182-004-MY3, 110-2811-E-182-507, CMRPD2J0031-33] (2022 SCIE, IF: 5.7, MULTISCIPLINARY SCIENCES: 16/73 = 21.23%)
152. Chen CH, Wen FH, Chou WC, Chen JS, Chang WC, Jason Chia-Hsun Hsieh, Tang ST*. “Factors associated

- with distinct prognostic-awareness-transition patterns over cancer patients' last 6 months of life.” *Cancer Medicine*. 2021 Nov;10(22):8029-8039. doi: 10.1002/cam4.4321. Epub 2021 Sep 30. PMID: 34590429; PMCID: PMC8607263. [NHRI-EX106-10208PI, MOST 105-2314-B-182-040-MY3, BMRP888] (2022 SCIE, IF: 4.0, ONCOLOGY: 96/241 = 39.83%)
153. Lin CY, Lee LY, Cheng NM, Lee SR, Tsai CY, Hsueh C, Fan KH, Wang HM, Jason Chia-Hsun Hsieh, Ng SH, Yeh CH, Lin CH, Tsao CK, Fang TJ, Huang SF, Lee LA, Kang CJ, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Liao CT*. “cN+pN0 disease does not portend a less favorable prognosis compared with cN0pN0 in patients with resected oral cavity squamous cell carcinoma.” *Cancer Medicine*. 2021 Oct;10(20):6947-6958. doi: 10.1002/cam4.4187. Epub 2021 Sep 23. PMID: 34558224; PMCID: PMC8525126. (2022 SCIE, IF: 4.0, ONCOLOGY: 96/241 = 39.83%)
154. Lee LY, Lin CY(共同第一), Cheng NM, Tsai CY, Hsueh C, Fan KH, Wang HM, Jason Chia-Hsun Hsieh, Ng SH, Yeh CH, Lin CH, Tsao CK, Fang TJ, Huang SF, Lee LA, Kang CJ, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Liao CT. “Poor tumor differentiation is an independent adverse prognostic variable in patients with locally advanced oral cavity cancer--Comparison with pathological risk factors according to the NCCN guidelines.” *Cancer Medicine*. 2021 Oct;10(19):6627-6641. doi: 10.1002/cam4.4195. Epub 2021 Sep 17. PMID: 34533269; PMCID: PMC8495291. (2022 SCIE, IF: 4.0, ONCOLOGY: 96/241 = 39.83%)
155. Tseng YT, Jason Chia-Hsun Hsieh, Hung CW, Chen CC, Lee SH, Lee LY, Chen SC. “Supportive Care and Unmet Needs in Upper Gastrointestinal Cancer Patients: Screening and Related Factors.” *International Journal of Environmental Research and Public Health*. 2021 Jul 31;18(15):8124. doi: 10.3390/ijerph18158124. PMID: 34360415; PMCID: PMC8345742. [CMRPG3E1881, CMRPF1H0131, CMRPF1K0021, CMRPF1K0022, CMRPF3K0011, MOST 108-2314-B-255-006-MY3.] (2021 SSCI IF: 4.614, PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 45/182 = 24.45 %)
156. Wu CE, Huang WK, Chou WC, Jason Chia-Hsun Hsieh, Chang JW, Lin CY, Yeh CN*, Chen JS*. “Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy.” *Cancers (Basel)*. 2021 Jun 23;13(13):3139. doi: 10.3390/cancers13133139. PMID: 34201707; PMCID: PMC8268608. [CMRPG3K0601, CMRPG3J0971~2, CRRPG3K0021~2, CMRPG3I0241~3, CRRPG3K0031~2, MOST 109-2314-B-182-080-MY3] (2022 SCIE IF: 5.2, ONCOLOGY: 72/241 = 29.88%)
157. Shao YY, Wang SY, Lin SM; Diagnosis Group,; Systemic Therapy Group(...Jason Chia-Hsun Hsieh..). “Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.” *JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION*. 2021 Apr;120(4):1051-1060. doi: 10.1016/j.jfma.2020.10.031. Epub 2020 Nov 14. PMID: 33199101. (2022 SCIE, IF: 3.2, MEDICINE, GENERAL & INTERNAL 69/167 = 41.32%)

158. Chen CH, Wen FH, Chou WC, Chen JS, Chang WC, Jason Chia-Hsun Hsieh, Tang ST. "Associations of prognostic-awareness-transition patterns with end-of-life care in cancer patients' last month." SUPPORTIVE CARE IN CANCER. 2022 Jul;30(7):5975-5989. doi: 10.1007/s00520-022-07007-4. Epub 2022 Apr 8. PMID: 35391576. (2022 SCIE, IF: 3.1, REHABILITATION: 15/68 = 22.06%)
159. Kang CJ, Wen YW, Lee SR, Ng SH, Lee LA, Lee LY, Hsueh C, Lin CY, Fan KH, Wang HM, Jason Chia-Hsun Hsieh, Yeh CH, Tsai CY, Lin CH, Tsao CK, Fang TJ, Huang SF, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Cheng NM, Liao CT. "Clinical outcomes of patients with pT4a and pT4b oral cavity squamous cell carcinoma who had undergone surgery: Results from a Taiwanese registry-based, nationwide cohort study." ORAL ONCOLOGY. 2022 Mar;126:105750. doi: 10.1016/j.oraloncology.2022.105750. Epub 2022 Feb 2. PMID: 35123256.[CMRPD1H0521,BMRPC5] (2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
160. Kang CJ, Wen YW, Lee SR, Lee LY, Hsueh C, Lin CY, Fan KH, Wang HM, Jason Chia-Hsun Hsieh, Ng SH, Yeh CH, Lin CH, Tsao CK, Fang TJ, Huang SF, Lee LA, Fang KH, Yen TC, Cheng NM, Tsai TY, Tai SF, Tsai CY. "Surgical Margins Status and Prognosis after Resection of Oral Cavity Squamous Cell Carcinoma: Results from a Taiwanese Nationwide Registry-Based Study". Cancers (Basel). 2021 Dec 21;14(1):15. doi: 10.3390/cancers14010015. PMID: 35008181; PMCID: PMC8749941. [CMRPD1H0521, CMRPG3I0011, CMRPG3I0012, CMRPG3I0013] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
161. Yi-Liang Shen E, Hung TM, Tsan DL, Cheng NM, Kang CJ, Huang SF, Hsu CL, Lin CY, Wang HM, Jason Chia-Hsun Hsieh, Cheng AJ, Fan KH, Tung-Chieh Chang J. "Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma. " RADIOTHERAPY AND ONCOLOGY. 2022 May 11:S0167-8140(22)00240-7. doi: 10.1016/j.radonc.2022.05.004. Epub ahead of print. PMID: 35568282. (2022 SCIE, IF: 5.7, Radiology,Nuclear Medicine & Medical Imaging 17/135 = 12.59%)
162. Teng W, Lin CC, Su CW, Lin PT, Hsieh YC, Chen WT, Ho MM, Wang CT, Chai PM, Jason Chia-Hsun Hsieh, Lin CY, Lin SM. "Combination of CRAFTY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma." American Journal of Cancer Research. 2022 Apr 15;12(4):1899-1911. PMID: 35530282; PMCID: PMC9077079. [CMRPG3J1341,CORPG3G0871, CORPG3H0641, CORPG3H0651, CORPG3H0661, CORPG3H0671, CMRPVVK0092, CMRPVVL0021),NMRPG3H0471, NMRPG3L0561] (2022 SCIE, IF: 5.3, Oncology 70/241 = 29.05%)
163. Chang PH, Lee CH, Wu TM, Yeh KY, Wang HM, Huang WK, Chan SC, Chou WC, Kuan FC, Kuo HC, Kuo YC, Hu CC, Jason Chia-Hsun Hsieh*(通訊作者). "Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer." Therapeutic Advances in Medical Oncology. 2022 Jul 15;14:17588359221110182. doi: 10.1177/17588359221110182. PMID:

- 35860832; PMCID: PMC9290096. [CMRPG2D0171, CMRPG2D0172, CMRPG2G0681, CMRPG2G0682, CMRPG2G0683, CMRPG2J0061-3, CMRPG2K0271, CMRPG2K0272, CMRPG2D0173, CMRPVVK0091, CMRPVVK0092, CMRPVVL0021, CMRPG3G1133, CMRPG3H0873, CMRPVVL0261](2022 SCIE, IF: 4.9 Oncology 78/241 = 32.37%)
164. Jason Chia-Hsun Hsieh, Yeh CT, (共同第一作者) Huang YH, Lai MW. "Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy." *ANTICANCER RESEARCH*. 2022 May;42(5):2479-2486. doi: 10.21873/anticancer.15726. PMID: 35489767. [CMRPG3J0681, CMRPG3J0682, CMRPG3J0683] (2022 SCIE IF: 2.0, Oncology 233/317 = 73.5%)
165. Chen MH, Chou WC, Hsiao CF, Jiang SS, Tsai HJ, Liu YC, Hsu C, Shan YS, Hung YP, Jason Chia-Hsun Hsieh, Chiu CH, Liu TC, Cho SF, Liu TW, Chao Y. "An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas." *ONCOLOGIST*. 2020 May;25(5):e782-e788. doi: 10.1634/theoncologist.2019-0490. Epub 2019 Dec 18. PMID: 31852810; PMCID: PMC7216444. [NRPB 104CT1007, MOST 108-2321-B-006/014, 108-2319-B-400-001](2022 SCIE IF: 5.8, ONCOLOGY: 59/241 = 24.48%)
166. Li SH, Wu MH, Wang HM, Hsu PC, Fang YF, Wang CL, Chu HC, Lin HC, Lee LY, Wu CY, Yang CT, Chen JS, Jason Chia-Hsun Hsieh*(通訊作者). "Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study." *International Journal of Molecular Sciences*. 2022 Sep 13;23(18):10661. doi: 10.3390/ijms231810661. PMID: 36142574; PMCID: PMC9505961. (2022 SCIE IF: 5.6, BIOCHEMISTRY & MOLECULAR BIOLOGY: 66/285 = 23.16%)
167. Gao X, Leow OQ, Chiu CH, Hou MM, Jason Chia-Hsun Hsieh, Chao YK. "Clinical Utility of Circulating Tumor Cells for Predicting Major Histopathological Response after Neoadjuvant Chemoradiotherapy in Patients with Esophageal Cancer." *Journal of Personalized Medicine*. 2022 Aug 31;12(9):1440. doi: 10.3390/jpm12091440. PMID: 36143225; PMCID: PMC9502866. [NMRPG3K6183, CORPG3L0331, CMRPVVK0092-3 MOST 109-2314-B-182A-125-MY3] (2022 SCIE IF: 3.508, HEALTH CARE SCIENCES & SERVICES 42/109 = 38.53%)
168. Kang CJ, Wen YW, Lee SR, Ng SH, Tsai CY, Lee LY, Chu YH, Lin CY, Fan KH, Wang HM, Jason Chia-Hsun Hsieh, Yeh CH, Lin CH, Tsao CK, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Cheng NM, Liao CT. "Towards an Improved Pathological Node Classification for Prognostic Stratification of Patients With Oral Cavity Squamous Cell Carcinoma: Results From a Nationwide Registry Study." *Frontiers in Oncology*. 2022 Jun 28;12:910158. doi: 10.3389/fonc.2022.910158. PMID: 35837108;

- PMCID: PMC9273780.[CMRPD1H0521, BMRPC55] (2022 SCIE IF: 4.7, ONCOLOGY 85/241 = 35.27%)
169. Yang CM, Yu JC, Chu PY, Jason Chia-Hsun Hsieh, Wu MH. "The Utilization of Tunable Transducer Elements Formed by the Manipulation of Magnetic Beads with Different Sizes via Optically Induced Dielectrophoresis (ODEP) for High Signal-to-Noise Ratios (SNRs) and Multiplex Fluorescence-Based Biosensing Applications." *Biosensors-Basel*. 2022 Sep 14;12(9):755. doi: 10.3390/bios12090755. PMID: 36140140; PMCID:PMC9496456. [CMRPD2L0171, CMRPD2I0012, CMRPD2L0051, CMRPD2J0031-33, MOST: 108-2221-E-182-060-MY3, 108-2628-E-182-002-MY3, 111-2923-E-182-001-MY3, 111-2221-E-182-023-MY3, 110-2221-E-182-030-MY2, 110-2221-E-182-004-MY3.] (2022 SCIE, IF: 5.4, CHEMISTRY,ANALYTICAL: 14/86 = 16.28%)
 170. Huang SF, Chong SW, Huang CW, Hsu HY, Pan KT, Hung CF, Wu TH, Lee CW, Jason Chia-Hsun Hsieh, Wang CT, Chai PM, Yu MC. "Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma." *Biomedicines*. 2022 Sep 14;10(9):2277. doi: 10.3390/biomedicines10092277. PMID: 36140381; PMCID: PMC9496215.[CMRPVJV0022, CMRPG1J0121](2022 SCIE, IF: 4.7, PHAMACOLOGY&PHARMACY 69/277 = 24.91%)
 171. Huang PW, Lin CY, Lee LY, Jason Chia-Hsun Hsieh, Hsu CL, Liao CT, Fan KH, Huang SF, Liao CT, Chang TC, Wang HM. "Maintenance tegafur-plus-uracil after adjuvant concurrent chemoradiotherapy may improve outcome for resected oral cavity squamous cell carcinoma with extranodal extension." *Frontiers in Oncology*. 2022 Sep 28;12:866890. doi: 10.3389/fonc.2022.866890. PMID: 36249049; PMCID: PMC9554642. (2022 SCIE IF: 4.7, ONCOLOGY 85/241 = 35.27%)
 172. Chen CY, Yang HW, Hsieh PH, Jason Chia-Hsun Hsieh, Wu MH*. "Development of a photothermal bead-based nucleic acid amplification test (pbbNAAT) technique for a high-performance loop-mediated isothermal amplification (LAMP)-based point-of-care test (POCT)." *Biosensors and Bioelectronics*. 2022 Nov 1;215:114574. doi: 10.1016/j.bios.2022.114574. Epub 2022 Jul 22. PMID: 35926394.) [MOST109-2221-E-110-006-MY3, MOST 110-2221-E-182-030-MY2, CMRPD2L0051] (2022 SCIE IF: 12.6, CHMISTRY,ANALYTICAL 2/86 = 2.33%)
 173. Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Jason Chia-Hsun Hsieh, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC*. "Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer." *International Journal of Cancer*. 2022 Nov 8. doi: 10.1002/ijc.34348. Epub ahead of print. PMID: 36346116. [CORPG3F0881] (2022 SCIE IF: 6.4, ONCOLOGY 52/241 = 21.58%)
 174. Liao CT, Lee LY, Lee SR, Ng SH, Liu TW, Chien CY, Lin JC, Wang CP, Terng SD, Hua CH, Chen TM, Chen WC, Tsai YT, Kang CJ, Tsai CY, Chu YH, Lin CY, Fan KH, Wang HM, Jason Chia-Hsun Hsieh, Yeh

- CH, Lin CH, Tsao CK, Yen TC, Cheng NM, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Wen YW. "Optimizing margin status for improving prognosis in patients with oral cavity squamous cell carcinoma: A retrospective study from the two highest-volume Taiwanese hospitals." *Frontiers in Oncology*. 2022 Nov 14;12:1019555. doi: 10.3389/fonc.2022.1019555. PMID: 36452510; PMCID: PMC9701708.[CMRPD1H0521, BMRPC55] (2022 SCIE IF: 4.7, ONCOLOGY 85/241 = 35.27%)
175. Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh YC, Chen WT, Ho MM, Chia-Hsun Hsieh, Wang CT, Chai PM, Lin CC, Lin CY, Lin SM. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. *Cancer Medicine*. 2023 Mar;12(6):7077-7089. doi: 10.1002/cam4.5506. Epub 2022 Dec 5. PMID: 36468578; PMCID: PMC10067067. (2022 SCIE, IF: 4.0, ONCOLOGY: 96/241 = 39.83%)
176. Chan SC, Yeh CH, Ng SH*, Lin CY, Wang JH, Chang JT, Cheng NM, Chang KP, Jason Chia-Hsun Hsieh. Prospective Investigation of 18FDG-PET/MRI with Intravoxel Incoherent Motion Diffusion-Weighted Imaging to Assess Survival in Patients with Oropharyngeal or Hypopharyngeal Carcinoma. *Cancers (Basel)*. 2022 Dec 12;14(24):6104. doi: 10.3390/cancers14246104. PMID: 36551590; PMCID: PMC9775681.[MOST 110-2314-B-303-014,MOST 111- 2314-B-303-006, MOST 104-2314-B-182A-091 - MY3.] (2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
177. Chien CY, Wang CP, Lee LY, Lee SR, Ng SH, Kang CJ, Lin JC, Terng SD, Hua CH, Chen TM, Chen WC, Tsai YT, Tsai CY, Chu YH, Lin CY, Fan KH, Wang HM, Chia-Hsun Hsieh, Yeh CH, Lin CH, Tsao CK, Cheng NM, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Wen YW, Liao CT. Indications for elective neck dissection in cT1N0M0 oral cavity cancer according to the AJCC eight edition: A nationwide study. *ORAL ONCOLOGY*. 2023 Mar 23;140:106366. doi: 10.1016/j.oraloncology.2023.106366. Epub ahead of print. PMID: 36965411. [CMRPD1H0521,BMRPC55](2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
178. Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Chia-Hsun Hsieh, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. *International Journal of Cancer*. 2023 Mar 15;152(6):1191-1201. doi: 10.1002/ijc.34348. Epub 2022 Dec 9. PMID: 36346116.[CORPG3F0881] (2022 SCIE IF: 6.4, ONCOLOGY 52/241 = 21.58%)
179. Chen CH, Wen FH, Chang WC, Chia-Hsun Hsieh, Chou WC, Chen JS, Tang ST. Associations of prognostic-awareness-transition patterns with emotional distress and quality of life during terminally ill cancer patients' last 6 months of life. *Psychooncology*. 2023 Mar 8. doi: 10.1002/pon.6119. Epub ahead of

- print. PMID: 36891618. [NHRI-EX106-10208PI, NHRI-EX111-10704PI, MOST108-2314-B-182-061-MY3,BMRP888]
180. Wen FH, Chia-Hsun Hsieh, Hou MM, Su PJ, Shen WC, Chou WC, Chen JS, Chang WC, Tang ST. Decisional-Regret Trajectories From End-of-Life Decision Making Through Bereavement. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2023 Jul;66(1):44-53.e1. doi: 10.1016/j.jpainsymman.2023.02.321. Epub 2023 Mar 7. PMID: 36889452.[MOST105-2314-B-182-040-MY3,NHRI-EX111-10704PI,BMRP888] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 181. Tsai CY, Wen YW, Lee SR, Ng SH, Kang CJ, Lee LY, Hsueh C, Lin CY, Fan KH, Wang HM, Chia-Hsun Hsieh, Yeh CH, Lin CH, Tsao CK, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Cheng NM, Liao CT. Early relapse is an adverse prognostic factor for survival outcomes in patients with oral cavity squamous cell carcinoma: results from a nationwide registry study. BMC Cancer. 2023 Feb 7;23(1):126. doi: 10.1186/s12885-023-10602-1. PMID: 36750965; PMCID: PMC9906940. [CMRPD1H0521,BMRPC55] (2022 SCIE, IF: 3.8, ONCOLOGY: 109/241 = 45.23%)
 182. Kuan WF, Chang FY, Chang JJ, Kuo HC, Hsieh, Chia-Hsun Hsieh, Su JF, Chen CL. Building high-capacity mesoporous adsorbents for fluoride removal through increased surface oxygen anions using organogel-assisted synthesis. Journal of Cleaner Production. 2023 Mar 14;401. doi: 10.1016/j.jclepro.2023.136784. [110-2222-E-182-002-MY3, 111-2221-E-032-003,109-2222-E-131-002-MY3, CMRPVVL0261, CMRPVVK0092] (2022 SCIE, IF: 11.1, ENVIRONMENTAL SCIENCES: 22/274 = 8.03%)
 183. Chen MH, Chia-Hsun Hsieh, Yang CY, Tsai HJ, Chen LT. Small Pancreas Neuroendocrine Tumors: How Small is Small? Journal of Cancer Research and Practice. 2023 Jun 16; 10(2): 50-56. doi: 10.4103/ejcrp.eJCRP-D-22-00030.
 184. Wen FH, Chia-Hsun Hsieh, Chou WC, Su PJ, Hou MM, Shen WC, Chen JS, Chang WC, Tang ST. Factors associated with cancer patients' distinct death-preparedness states. Psycho-Oncology. 2023 Jul;32(7):1048-1056. doi: 10.1002/pon.6146. Epub 2023 Apr 27. PMID: 37114337.[MOST 104-2314-B-182-027-MY3, BMRP888, NHRI-EX111-10704PI]
 185. Yang CM, Chu PY, Wu AY, Hsieh PH, Chia-Hsun Hsieh, Wu MH. Development of an Optically Induced Dielectrophoresis (Odep) Microfluidic System with a Virtual Gel Permeation Chromatography (Gpc)-Like Mechanism for the High-Performance Sorting and Separation of Microparticles Based on Their Size Differences. Sensors and Actuators B: Chemical.2023 Aug 12;395. doi.org/10.1016/j.snb.2023.134443. [110-2221-E-182-004-MY3, 110-2221-E-182-030-MY2, 111-2923-E-182-001-MY3, 111-2221-E-182-023-MY3, CMRPD2J0033, CMRPD2L0051CMRPD2M0291, CMRPD2L0171] (2022 SCIE: 8.4, INSTRUMENT & INSTRUMENTATION: 1/63 = 1.59%)
 186. Wen FH, Chia-Hsun Hsieh, Chou WC, Su PJ, Hou MM, Shen WC, Chen JS, Chang WC, Tang ST. Factors associated with cancer patients' distinct death-preparedness states. Psychooncology. 2023 Jul;32(7):1048-

1056. doi: 10.1002/pon.6146. Epub 2023 Apr 27. PMID: 37114337.[MOST 104-2314-B-182-027-MY3,NHRI-EX111-10704P,BMRP888]
187. Chu PY, Yang CM, Huang KL, Wu AY, Chia-Hsun Hsieh, Chao AC, Wu MH. Development of an Optically Induced Dielectrophoresis (ODEP) Microfluidic System for High-Performance Isolation and Purification of Bacteria. *Biosensors-Basel*. 2023 Oct 25;13(11):952. doi: 10.3390/bios13110952. PMID: 37998128; PMCID: PMC10669672.[110-2221-E-182-004-MY3, 110-2221-E-182-030-MY2,CMRPD2J0033,CMRPD2L0051, CMRPD2M0291, KMHU111-1M50](2022 SCIE, IF: 5.4, CHEMISTRY,ANALYTICAL: 14/86 = 16.28%)
 188. Chao YK, Chang CB, Chang YC, Chan SC, Chiu CH, Ng SH,Jason Chia-Hsun Hsieh, Wang JH. Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy. *Cancer Imaging*. 2023 Nov 6;23(1):109. doi: 10.1186/s40644-023-00630-2. PMID: 37932848; PMCID: PMC10629192. [107-2314-B-182 A-064,108-2314-B-182 A-021, CMRPG 3J0731&2,TCMF-A 110-03, TCMF-A110-03(111), TCMF-A 110-03(112)] (2022 SCIE IF:4.9, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 24/135 = 17.7%)
 189. Wen FH, Chia-Hsun Hsieh, Shen WC, Hou MM, Su PJ, Chou WC, Chen JS, Chang WC, Tang ST. Associations Between Surrogates' Decisional Regret Trajectories and Bereavement Outcomes.*Journal of the National Comprehensive Cancer Network*. 2023 Nov;21(11):1141-1148.e2. doi: 10.6004/jnccn.2023.7053. PMID: 37935096. [MOST 105-2314-B-182-040-MY3,NHRI-EX111-10704PI,BMRP888](2022 SCIE, IF: 13.4, ONCOLOGY: 19/241 = 7.88%)
 190. Nguyen TNA, Huang PS, Chu PY, Chia-Hsun Hsieh, Wu MH. Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters. *Cancers (Basel)*. 2023 Nov 11;15(22):5372. doi: 10.3390/cancers15225372. PMID: 38001632; PMCID: PMC10670359.[110-2221-E-182-004-MY3, 110-2811-E-182-507, 111-2811-E-182-009,CMRPD1M0561, CMRPD1M0562, CMRPD2M0291](2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
 191. Wen FH, Chia-Hsun Hsieh, Su PJ, Shen WC, Hou MM, Chou WC, Chen JS, Chang WC, Tang ST. Factors Associated With Family Surrogate Decisional-Regret Trajectories. *JOURNAL OF PAIN AND SYMPTOM MANAGEMENT*. 2024 Mar;67(3):223-232.e2. doi: 10.1016/j.jpainsymman.2023.11.013. Epub 2023 Nov 28. PMID: 38036113.[MOST 104-2314-B-182-027-MY3, BMRP888, NHRI-EX111-10704PI] (2022 SCIE IF: 4.7, MEDICINE, GENERAL & INTERNAL: 45/167 = 26.95%)
 192. Li HP, Huang CY, Lui KW, Chao YK, Yeh CN, Lee LY, Huang Y, Lin TL, Kuo YC, Huang MY, Fan HC, Lin AC,Chia-Hsun Hsieh, Chang KP, Lin CY, Wang HM, Chao M, Liu JS, Chang YS, Hsu CL. Nasopharyngeal carcinoma patient-derived xenograft mouse models reveal potential drugs targeting cell cycle, mTOR, and autophagy pathways. *Translational Oncology*. 2023 Dec;38:101785. doi: 10.1016/j.tranon.2023.101785. Epub 2023 Sep 13. PMID: 37713975; PMCID: PMC10509698.[CMRPG3J0301~3, 3J0331~3, CORPG3J0161~2,CORPG3J0271~3, CMRPD1H0582, CMRPD1K0142, CMRPD1K0651, CMRPD1L0351, CMRPD1N0161,MOST-111-2314-B-182-046,,MOST-108-2311-B-182-002, MOST-111-2320-B-182-021, NSTC-112-2320-B-182-041-MY3,

- EMRPD1K0281, EMRPD1M0281] (2022 SCIE IF: 5.0, ONCOLOGY 77/241 = 31.95%)
193. Hsu HC, Chung WH, Lin YC, Yang TS, Chang JW, Chia-Hsun Hsieh, Hung SI, Lu CW, Chen JS, Chou WC, Wang CW. Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions. *Allergology International*. 2024 Apr 8;S1323-8930(24)00041-8. doi: 10.1016/j.alit.2024.03.003. Epub ahead of print. PMID: 38594174. (2022 SCIE IF: 6.8, ALLERGY 6/28 = 21.42%)
 194. Kang CJ, Lee LY, Ng SH, Lin CY, Fan KH, Chen WC, Lin JC, Tsai YT, Lee SR, Chien CY, Hua CH, Ping Wang C, Chen TM, Terng SD, Tsai CY, Wang HM, Chia-Hsun Hsieh, Yeh CH, Lin CH, Tsao CK, Cheng NM, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Wen YW, Liao CT. Should sub-millimeter margins be deemed positive in oral cavity squamous cell carcinoma? *Oral Oncology*. 2024 Apr;151:106745. doi: 10.1016/j.oraloncology.2024.106745. Epub 2024 Mar 8. PMID: 38460286.(2022 SCIE, IF: 4.8, DENTISTRY, ORAL SURGERY & MEDICINE 8/91 = 8.79%)
 195. Hsu JL, Leu WJ, Hsu LC, Chia-Hsun Hsieh, Guh JH. Doxazosin inhibits vasculogenic mimicry in human non-small cell lung cancer through inhibition of the VEGF-A/VE-cadherin/mTOR/MMP pathway. *ONCOLOGY LETTERS*. 2024 Feb 22;27(4):170. doi: 10.3892/ol.2024.14303. PMID: 38455663; PMCID: PMC10918514.[NSTC 112-2320-B-255-014,ZURPF3N0091] (2022 SCIE IF:2.9 Oncology:163/241 = 67.63%)
 196. Su CW, Teng W, Shen EY, Huang BS, Lin PT, Hou MM, Wu TH, Tsan DL, Chia-Hsun Hsieh, Wang CT, Chai PM, Lin CY, Lin SM, Lin CC. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma. *Oncologist*. 2024 Mar 26:oyae048. doi: 10.1093/oncolo/oyae048. Epub ahead of print. PMID: 38530254.(2022 SCIE IF:5.8, ONCOLOGY:59/241 = 24.48%)
 197. Chen TM, Terng SD, Lee LY, Lee SR, Ng SH, Kang CJ, Lin JC, Chien CY, Hua CH, Wang CP, Chen WC, Tsai YT, Tsai CY, Lin CY, Fan KH, Wang HM, Chia-Hsun Hsieh, Yeh CH, Lin CH, Tsao CK, Cheng NM, Fang TJ, Huang SF, Lee LA, Fang KH, Wang YC, Lin WN, Hsin LJ, Yen TC, Wen YW, Liao CT. Is elective neck dissection justified in cT2N0M0 oral cavity cancer defined according to the AJCC eighth edition staging system? *Cancer Medicine*. 2024 Jan 3;13(1):e6894. doi: 10.1002/cam4.6894. Epub ahead of print. PMID: 38169115; PMCID: PMC10807631.[CMRPD1H0521, BMRPC55](2022 SCIE, IF: 4.0, ONCOLOGY: 96/241 = 39.83%)
 198. Fan KH, Kang CJ, Lin CY, Ng SH, Wang HM, Chia-Hsun Hsieh, Yeh CH, Lin CH, Tsao CK, Huang SF, Fang KH, Wang YC, Chang JT, Liao CT, Lee LY. Quantitative Measurement of Perineural Invasion for Prognosis Analysis of Oral Cavity Cancer Treated by Radical Surgery With or Without Adjuvant Therapy. *TECHNOLOGY IN CANCER RESEARCH & TREATMENT*. 2023 Jan-Dec;22:15330338231176366. doi: 10.1177/15330338231176366. PMID: 37264638; PMCID: PMC10272672.(2022 SCIE, IF: 2.8, ONCOLOGY: 168/241 = 34.88%)

199. Kuo YC, Chuang CH, Kuo HC, Lin CT, Chao A, Huang HJ, Wang HM, Jason Chia-Hsun Hsieh, Chou HH. Circulating tumor cells help differentiate benign ovarian lesions from cancer before surgery: A literature review and proof of concept study using flow cytometry with fluorescence imaging. *ONCOLOGY LETTERS*. 2024 Mar 26;27(5):234. doi: 10.3892/ol.2024.14367. PMID: 38596263; PMCID: PMC11003220.(2022 SCIE IF:2.9 Oncology:163/241 = 67.63%)
200. Lu HJ, Hsieh MC, Wang HM, Jason Chia-Hsun Hsieh, Yen CJ, Wu SY, Huang HC, Wang HC, Chu PY, Chen TH, Chien CY, Huang TL, Chang YF, Hua CH, Lien MY, Chen JP, Lu WC, Lin JC, Wang CC, Liu YC, Yang MH, Lou PJ. Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database. *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*. 2024 May;46(5):1063-1073. doi: 10.1002/hed.27681. Epub 2024 Feb 22. PMID: 38385970. (2022 SCIE, IF: 2.9, OTORHINOLARYNGOLOGY: 8/43 = 18.6%)
201. Chang PH, Chen HY, Chang YS, Su PJ, Huang WK, Lin CF, Jason Chia-Hsun Hsieh, Wu CT. Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy. *Cancers (Basel)*. 2024 Feb 23;16(5):894. doi: 10.3390/cancers16050894. PMID: 38473256; PMCID: PMC10930778.(2022 SCIE IF: 5.2, ONCOLOGY:72/241 = 29.88%)
202. Chang CH, Huang SH, Huang HY, Lin MH, Lee CS, Lee HF, Hsieh JC, Cheng CY. Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study. *Therapeutic Advances in Medical Oncology* 2024 Jan 18;16:17588359231221907. doi: 10.1177/17588359231221907. PMID: 38249337; PMCID: PMC10798069.[CMRPVVL0211, CORPVVM0051] (2022 SCIE, IF: 4.9 Oncology 78/241 = 32.37%)
203. Peng, J. R., **Hsieh, J. C. H.**, Chang, C. H., Chuang, C., Wang, Y. C., Chen, T. Y., ... & Lee, H. F. (2024). Cardiovascular and venous thromboembolism risks in cancer patients treated with immune checkpoint inhibitors compared to non-users-a multi-center retrospective study. *Cardio-Oncology*, 10(1), 59.
204. Hsu, C. L., Wen, Y. W., Wang, H. M., **Hsieh, C. H.**, Liao, C. T., Lee, L. Y., ... & Liao, C. T. (2024). Prognostic impact of bridge or neoadjuvant induction chemotherapy in patients with resected oral cavity cancer: A nationwide cohort study. *Cancer Medicine*, 13(15), e70061.
205. Tsai, K. Y., Huang, P. S., Chu, P. Y., Nguyen, T. N. A., Hung, H. Y., **Hsieh, C. H.**, & Wu, M. H. (2024). Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence. *Cancers*, 16(13), 2316.
206. Chu, P. Y., Wu, A. Y., Tsai, K. Y., **Hsieh, C. H.**, & Wu, M. H. (2024). Combination of an Optically Induced Dielectrophoresis (ODEP) Mechanism and a Laminar Flow Pattern in a Microfluidic System for the Continuous Size-Based Sorting and Separation of Microparticles. *Biosensors*, 14(6), 297.
207. Lin, C. Y., Huang, P. W., **Hsieh, C. H.**, Hsu, C. L., Liao, C. T., Huang, S. F., ... & Wang, H. M. (2024). Prophylactic Versus Reactive Megestrol Acetate Use for Critical Body Weight Loss in Patients with Pharyngeal and Laryngeal Squamous Cell Carcinoma Undergoing Concurrent Chemoradiotherapy. *Nutrition and Cancer*, 1-10.

208. Lu, H. J., Hsieh, M. C., Wang, H. M., **Hsieh, J. C. H.**, Yen, C. J., Wu, S. Y., ... & Lou, P. J. (2024). Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database. *Head & Neck*, 46(5), 1063-1073.
209. Lin CH, YC Kou, HC Kou, Jason CH Hsieh*. Absence of Survival Impact from Hepatitis During Immunotherapy in 193 Patients with Advanced Hepatocellular Carcinoma – An Observational Study from Taiwan. 2024 (accept for publication)

ABSTRACTS/POSTERS

1. Chia-Hsun Hsieh, John WC Chang, Jia-Juan Hsieh, Todd Hsu, Shiu-Feng Huang, Chun-Ta Liao, Hung-Ming Wang. Identification of Epidermal Growth Factor Receptor Mutations in Patients with Head and Neck Squamous Cell Carcinoma. (Annual Meeting of Taiwan Society of Internal Medicine. 2009. Best Poster Award.)
2. Chia-Hsun Hsieh, Yung-Chang Lin, Chaung-Chi Liaw, Rong-Nan Ching, Cheng-Hsu Wang, Jen-Shi Chen. Octreotide Long-acting Release for Patients with Functional Gastroenteropancreatic Neuroendocrine Tumors - An Experience in Chang Gung Memorial Hospital. . The 15th Taiwan Joint Cancer Conference, 2010.
3. Chia-Hsun Hsieh, Wen-Chi Chou, Yung-Chang Lin, Chaung-Chi Liaw, Rong-Nan Chien, Cheng-Hsu Wang, Hung-Chih Hsu, Jen-Shi Chen. Octreotide Long-acting Release Therapy for Patients with Functioning and Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Analysis in Chang-Gung Memorial Hospital. The 9th European Neuroendocrine Tumor Conference Meeting in Denmark, 2012.
4. Chia-Hsun Hsieh, Cheng-lung Hsu, Cheng-Hsu Wang, Chaung-Chi Liaw, Jen-Shi Chen, Hsien-Kun Chang, Tsai-Shen Yang, John Wen-Cheng Chang; Yung-Chang Lin; Chi-Ting Liao, Ngan-Ming Tsang, Joseph Tung-Chieh Chang, Shu-Hang Ng, Hung-Ming Wang. Cisplatin, Tegafur-Uracil (UFUR) and Leucovorin Plus Mitomycin C as an Outpatient Regimen for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Trial. The 16th Taiwan Joint Cancer Conference, 2011. & 21th Asia Pacific Cancer Conference, 2011 in Malaysia
5. Chia-Hsun Hsieh, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Chemoradiotherapy with Cisplatin, Tegafur-uracil plus Leucovorin for Patients with Locally Advanced Nasopharyngeal Carcinoma: A Phase II Trial (2012 17th Taiwan Joint Cancer Conference, Accepted as Good Article Award)
6. Chia-Hsun Hsieh, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Outcome analysis of high risky oral cavity squamous cell carcinoma treated with surgery plus adjuvant chemoradiotherapy with cisplatin 100 mg/m² every 3week. (2012 17th Taiwan Joint Cancer Conference)
7. Chia-Hsun Hsieh, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Preliminary Report of

- Neoadjuvant Chemotherapy of Docetaxel/Cisplatin/5-fluorouracil (TPF) in Unresectable Head & Neck Squamous Cell Carcinoma. (2012 17th Taiwan Joint Cancer Conference)
8. Song-Bin Huang, Min-Hsien Wu, Chia-Hsun Hsieh, Chih-Liang Yang, Yen-Heng Lin, Hung-Chih Lin, Ching-Ping Tseng and Gwo-Bin Lee. An optically-induced dielectrophoretic (ODEP) microfluidic platform for isolation of circulating tumor cells (CTCS) after conventional CTC isolation process. (2012 micro TAS meeting, Okinawa, Japan)
 9. Sanger Hung-Chih Lin, Min-Hsien Wu, Hung-Chih Hsu, Chia-Hsun Hsieh, Ju-Chien Cheng, Ching-Ping Tseng. A new approach to isolate label-free and viable circulating tumor cells for monitoring cancer patient treatment response. (2012 AACR Abstract #2383)
 10. Sanger Hung-Chih Lin, Chia-Hsun Hsieh, Ching-Ping Tseng. A new approach to isolate label-free and viable circulating tumor cells for monitoring cancer patient treatment response. (2013 CellTech, in San Diego Abstract, *Best Abstract Award*)
 11. Hsiao-Hsiang Cheng, Chia-Hsun Hsieh, Cheng Wei Hong, Yung-Feng Lo, Li-Ying Ou, Hsin-Yi Cheng, Jia-Juan Hsieh, Su-Peng Yeh, John Wen-Cheng Chang. Result of compassionate use of Dabrafenib (BRAF inhibitor) in Melanoma with *BRAF* V600 Mutation. (2013 Taipei, 18th Taiwan Joint Cancer Conference)
 12. Chia-Hsun Hsieh, Chiao-En Wu, Yung-Feng Lo, Jia-Juan Hsieh, Hsin-Yi Cheng, Yung-Chi Shen, Yung-Chang Lin, John Wen-Cheng Chang. A study of the activation of BRAF and mTOR pathway in melanomas in Taiwan. (2013 Taipei, 18th Taiwan Joint Cancer Conference)
 13. Ke-Cing Li, Yi-Dao Chen, Chia-Hsun Hsieh, Min-Hsien Wu*. Primary Cancer Cell In Various Cell Culture Model—Physiological Differences and Chemosensitivity Of Anticancer Drug Test. 2013 醫工年會
 14. Jason Chia-Hsun Hsieh, Hung-Chih Lin, Hung-Chih Hsu, John Wen-Chen Chang, Ching-Ping Tseng. Circulating tumor cells enriched by the negative selection system PowerMag is a useful predictor for treatment response of metastatic colorectal cancer patients. (Poster Presentation in 2014 AACR, San Diego, USA.)
 15. Jason Chia-Hsun Hsieh, Yu-Ling Cheng, Li-Yu Lee, Chiao-En Wu, Wen-Kuan Huang, Yung-Feng Lo, Jia-Juan Hsieh, Hsin-Yi Cheng, Yung-Chi Shen, Yung-Chang Lin, John Wen-Cheng Chang. A Study of BRAF Mutation and the Expression of MAPK and mTOR Pathway of Melanomas in Taiwan. (Poster Presentation in 2014 The 29th Joint Annual Conference of Biomedical Science. Taipei, Taiwan.)
 16. Jason Chia-Hsun Hsieh, Hung-Chih Lin, Hung-Chih Hsu, John Wen-Cheng Chang, Ching-Ping Tseng. 4817: Circulating tumor cells enriched by the negative selection system PowerMag is a useful predictor for treatment response of metastatic colorectal cancer patients (2014 AACR, San Diego)
 17. Chia-Hsun Hsieh, Ching-Ping Tseng, Hung-Chih Lin, , Hung-Ming Wang, Ju-Chien Cheng. 4830: Prognostic value of circulating tumor cells with podoplanin expression in locally advanced and metastatic head and neck squamous cell carcinoma. (2014 AACR, San Diego)
 18. Chia-Hsun Hsieh, Hung-Ming Wang. A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of pharynx or larynx. (Poster Presentation in ACOS 2014, Taipei.)
 19. Chia-Hsun Hsieh, Chiao-En Wu, Yung-Feng Lo, Jia-Juan Hsieh, Hsin-Yi Cheng, Yung-Chi Shen, Yung-Chang Lin, John Wen-Cheng Chang. BRAF Mutation and The Activation of mTOR Pathway in Taiwanese Melanomas. (Poster Presentation. 2014 Taiwan Joint Cancer Conference. Taipei)
 20. Chia-Hsun Hsieh, Yung-Chang Lin, Chaung-Chi Liaw, Rong-Nan Ching, Cheng-Hsu Wang, Chuang Hui-Chieh, Jen-Shi Chen. The Somatostatin Analogs Therapy for Patients with Neuroendocrine Tumors - An Experience in Taiwan (Poster Presentation. 2014 Taiwan Joint Cancer Conference. Taipei)
 21. IPCCx10 2014
 22. Tzu-Keng Chiu (106529), Chia-Hsun Hsieh (106577), Hsiao Hung-Bo (106576), Min-Hsien Wu (106573). The Label-free Detection of Circulating Tumor Cells (CTCs) Using A Microfluidic Optical-based Sensing Device. (Poster Presentation in 2015 10th IEEE, Xian, China.)
 23. 257P; Real-world experience of sequential therapies including cytokine/immunotherapy of metastatic renal cell carcinoma in Taiwan. (accepted Poster presentation in ESMO Asia 2015, Singapore.)
 24. Po-Jung Su, Min-Hsien Wu, Hung-Ming Wang, Wen-Kuan Huang, Chiao-En Wu, Hung-Chih Hsu, Yin-Kai Chao, Chen-Kan Tseng, Tzu-Keng Chiu, Nina Ming-Jung Lin, Siou-Ru Ye, Jane Ying-Chieh Lee, Jason Chia-Hsun Hsieh “Circulating Tumor Cells as An Independent Prognostic Factor in Patients with Advanced Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy” Poster Presentation.

- 2016 Taiwan Joint Cancer Conference. Taipei)
25. Hung-Ming Wang, Tyler Min-Hsien Wu, Yung-Chang Lin, Nina Ming-Jung Lin, Siou-Ru Ye, Jane Ying-Chieh Lee, Jason Chia-Hsun Hsieh “ The Clinical Relevance of Immune cells and Circulating Tumor Cells in Patients with Head and neck Cancer.”Poster Presentation. 2016 Taiwan Joint Cancer Conference. Taipei
26. Chia-Hsun Hsieh. Circulating tumor cells at disease recurrence in patients with head and neck cancer after curative therapy. AACR poster Abstract Control Number: 5091. 2017. Washington DC.
27. Kuan Yu Hsieh, Sheng-Jen Cheng, Chia-Hsun Hsieh and Guan-Yu Chen
Title: A Nano-bio Interfaced Microfluidic System for Capturing Circulating Tumor Cells (CTCs) and Circulating Tumor Microemboli (CTMs) 2017 BME Annual Symposium.
28. Identification and Classification of Different Phenotypic CTCs and CTMs by image processing and machine learning based techniques. (生醫材料及藥物制放 2018 年會暨研討會)
29. CTC And CtDNA Profiling To Detect 6 NCCN-Guideline Recommended Classes Of Alterations For Immunotherapy And Targeted Therapy Selection Using Sample From A Single Blood Draw(AACR Annual Meeting 2018, April 14 - 18, Chicago, Illinois.-3635)
30. Analytical Validation Of A Novel Circulating Tumor DNA Detection Platform For Targeted And Immunotherapy Selection (AACR Annual Meeting 2018, April 14 - 18, Chicago, Illinois. 3652-)
31. Shiue-Luen Chen, Sheng-Jen Cheng, Kuan-Yu Hsieh, Chong-You Chen, Chung-Min Chung, Chia-Hsun Hsieh, Shien-Fong Lin, Guan-Yu Chen
Title: Early Detection of Cancer Metastasis by Graphene Oxide Based Microfluidic System for Exosome Capturing (2018 International Symposium on Engineering and Applied Science, August 7-9, 2018, Guam, U.S.A)
32. Sheng-Jen Cheng, Kuan-Yu Hsieh, Chia-Hsun Hsieh, Guan-Yu Chen Title: Graphene Oxide-Based Microfluidic System for Efficient Capture of Circulating Tumor Cells and Microemboli (2018 TERMIS World Congress, September 4-7, 2018, Kyoto International Conference Center, Kyoto, Japan)
33. Poster Presentation. 2018 Taiwan Joint Cancer Conference. Taipei
34. Poster Presentation. 2018 Taiwan Joint Cancer Conference. Taipei
35. Liquid Biopsy: Sensitive and Specific Nano-Biointerface for Accurate Capture and Detection.生物技術與生化工程學會年會(ACB2019)
36. Exosome Separating and Capturing by Graphene Oxide Based Microfluidic System.生物技術與生化工程學會年會(ACB2019)
37. Enhanced Circulating Tumor DNA Detection on Functionalized Graphene Oxide Nanosheets through Mild Thermal Annealed: Fluorescent Sensor for Thyroid Cancer Denoises. 生物技術與生化工程學會年會 (ACB2019)
38. Huangpin B. Hsieh, Jen-chia Wu, Feng-Ming Lin, Julian Lucas, Alex Atkins, Pratyush Gupta, Hung-Jen Shao, Yen-Lin Chen, Wen-Jie Huang, Chia-Hsun Hsieh, Ruey Kuen Hsieh, Kuo-Wei Chen, Ming-Hong Yen, Mana Javey, Shih-En Chang, Twinkal Marfatia, Drew Watson, Mahul Amin, Ashish Nimgaonkar, Oscar Segurado and Rui Mei. "Abstract 3635: CTC and ctDNA profiling to detect 6 NCCN-guideline recommended classes of alterations for immunotherapy and targeted therapy selection using sample from a single blood draw" 2018 AACR, Chicago. U.S.
39. Tsai Ming Hung, Hung-Chih Lai, Alex Atkins, Si-Hong Lu, Wen-Tsung Huang, Tony Tzeng, Chia-Hsun Hsieh, Yu-lin Lin, Su-Peng Yeh, Shih-En Chang, Mana Javey, Rui Mei . "Clinical utility of a novel circulating tumor DNA test in guiding targeted therapy selection." (2018) ASCO meeting, Chicago. U.S.
40. Ting-Shiuan Yeh, Chia-Hsun Hsieh*. Circulating tumour cells and circulating stem-like cancer cells were prognostic factors in metastatic breast cancer. 2018 ESMO meeting, Munich. Germany
41. Chen, M. H., Chou, W. C., Hsiao, C. F., Liu, Y. C., Hsu, C., Yanshen, S., ... & Cho, S. F. (2019). An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14). 2020 ASCO poster.
43. Hsieh KY, Chung CM, Jason Chia-Hsun Hsieh, Chen GY*. “A Graphene Oxide-interfaced Microfluidics System for Isolating and Capturing Circulating Tumor Cells and Microemboli.” Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings- 2021 Nov;2021:7260-7263. doi: 10.1109/EMBC46164.2021.9629506. PMID: 34892774.
44. Hsieh, T. T., Lee, K. H., **Hsieh, J. C. H.**, & Chang, Y. C. (2024). Comparing literature-based cell-free miRNA panels to whole genome miRNA screening for cancer detection. *Journal of Clinical Oncology*, 42(16_suppl), e13587-e13587.
45. **Hsieh, J. C. H.**, Hsieh, T. T., Lee, K. H., Tu, Y. H., Chang, P. Y., Wu, E. Y. H., ... & Lu, Y. J. (2024). Constructing a machine learning-based non-invasive liquid biopsy model for lung cancer detection via miRNA sequencing.

46. Hsu, H. C., Chung, W. H., Lin, Y. C., Yang, T. S., Chang, J. W. C., **Hsieh, C. H.**, ... & Wang, C. W. (2024). Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions. *Allergy International*.

ORAL PRESENTATION in International Conference

1. Chia-Hsun Hsieh, Cheng-lung Hsu, Cheng-Hsu Wang, Chaung-Chi Liaw, Jen-Shi Chen, Hsien-Kun Chang, Tsai-Shen Yang, John Wen-Cheng Chang; Yung-Chang Lin; Chi-Ting Liao, Ngan-Ming Tsang, Joseph Tung-Chieh Chang, Shu-Hang Ng, Hung-Ming Wang. Cisplatin, Tegafur-Uracil and Leucovorin Plus Mitomycin C as an Outpatient Regimen for Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Trial. (SEMBA conference, 2012, Taichung, Taiwan)
2. Chia-Hsun Hsieh, Cheng-Lung Hsu, Tung-Chieh Joseph Chang, Chien-Yu Lin, Kang-Hsing Fan, Shiang-Fu Huang, Hung-Jan Kang, Chun-Ta Liao, I-How Chen, Hung-Ming Wang. Chemoradiotherapy with Cisplatin, Tegafur-uracil plus Leucovorin for Patients with Locally Advanced Nasopharyngeal Carcinoma: A Phase II Trial (2012 17th Taiwan Joint Cancer Conference, Accepted as Good Poster Award)
3. Chia-Hsun Hsieh, Yung-Chang Lin. A Randomized Controlled, Double-blind Phase II Trial of BKM120 plus Metformin Concomitantly with First-line Paclitaxel Therapy versus Metformin plus Paclitaxel in Non-diabetic Patients with HER-2-negative, Locally advanced or Metastatic Breast Cancer. (2012 1st MD Anderson J-HOPE Program, Tokyo, Japan)
4. Chia-Hsun Hsieh (Speaker). Identifying and Management for Everolimus-associated Pneumonitis. (Speaker). MD Anderson GU oncology conference. 2013 in Linkou, Taiwan.
5. Chia-Hsun Hsieh (Speaker). Improving Outcomes in Metastatic Renal Cell Carcinoma by SEQUENCING THERAPY and Interpretation from Taiwanese Experience. At 2nd World Congress of Endourology and SWL (WCE; Sep, 5, 2014).
6. Chia-Hsun Hsieh (Speaker). The Management of Complicated neuroendocrine tumors (unknown primary site and functional neuroendocrine tumor). (第十屆全國胃癌大會、神經內分泌腫瘤專場) 2015, June, Beijing, China
7. Chia-Hsun Hsieh (Speaker). Cisplatin intolerance in head and neck cancer. 2016, August, Seoul, South Korea.
8. Chia-Hsun Hsieh. Circulating tumor cells at disease recurrence in patients with head and neck cancer after curative therapy. AACR poster Abstract Control Number: 5091. 2017. Washington DC.
9. Kuan Yu Hsieh, Sheng-Jen Cheng, Chia-Hsun Hsieh and Guan-Yu Chen
Title: A Nano-bio Interfaced Microfluidic System for Capturing Circulating Tumor Cells (CTCs) and Circulating Tumor Microemboli (CTMs) 2017 BME Annual Symposium.
10. Shiue-Luen Chen, Sheng-Jen Cheng, Kuan-Yu Hsieh, Chong-You Chen, Chung-Min Chung, Chia-Hsun Hsieh, Shien-Fong Lin, Guan-Yu Chen
Title: Early Detection of Cancer Metastasis by Graphene Oxide Based Microfluidic System for Exosome Capturing (2018 International Symposium on Engineering and Applied Science, August 7-9, 2018, Guam, U.S.A)
11. Sheng-Jen Cheng, Kuan-Yu Hsieh, Chia-Hsun Hsieh, Guan-Yu Chen
Title: Graphene Oxide-Based Microfluidic System for Efficient Capture of Circulating Tumor Cells and Microemboli (2018 TERMIS World Congress, September 4-7, 2018, Kyoto International Conference Center, Kyoto, Japan)
12. Exosome Separating and Capturing by Graphene Oxide Based Microfluidic System. 生物技術與生化工程學會年會(ACB2019)
13. Enhanced Circulating Tumor DNA Detection on Functionalized Graphene Oxide Nanosheets through Mild Thermal Annealed: Fluorescent Sensor for Thyroid Cancer Denoises. 生物技術與生化工程學會年會

(ACB2019)

14. ESMO Asia. (Singapore) 2018. Oral Presentation.

15. ESMO Asia. (Singapore) 2019. Mini-oral presentation.

16. ASCO meeting 2020. Oral poster presentation.

17. Jason Chia-Hsun Hsieh, Tsung-Ting Hsieh, Ko-Han Lee, Yu-Chuan Chang

Title: Guidance on modeling circulating miRNA to distinguish multiple cancer types by an observation of large-scale open data. 2023 ASCO Annual Meeting

PATENT

1. 用於微型化三維細胞培養的高通量灌流式微流體細胞培養晶片" 中華民國專利, 發明人: 吳旻憲、王士修、蔡宛真、張毓翰、謝佳訓、劉彥廷、崔占峰 (核准日期: 2014/05/21 專利號碼: I438273 申請號: **1001077435** 專利期限: **2014/05/21-2031/03/07** 專利權人: 長庚大學)
2. "Microfluidic Chip for High-Throughput Perfusion-based Three-Dimensional Cell Culture" Wu, M. H., Cui, Z.F., Wang, S.S., Tsai, W.C., Chang, Y.H., Hsieh, C.H., Liu, Y.T. US patent (Patent No. US 9068281 B2, Date of Patent: 2015/6/30, Patent filing No. 13/241123, Filing date: 2011/9/22)
3. "Method and Apparatus for Performing Contactless Optically - Induced Dielectrophoresis for Separation of Circulating Tumor Cells" Wu, M. H., Hsieh, C. H., Wang, H. M., Chou, W. P., Chiu, T. K. (Patent No. US 10456791 B2, Date of Patent: 2019/10/29, Patent filing No. 15/366591, Filing date: 2016/12/01)
4. "篩檢血液中循環腫瘤細胞之方法" 中華民國專利, 發明人: (核准日期: 2019/04/11 專利號碼: I656344 申請號: **105100249** 專利期限: **2019/04/11-2036/01/05** 專利權人: 長庚大學)"
5. "利用非接觸式與自動辨識的血液循環腫瘤細胞純化分離之方法及裝置", 中華民國發明專利, 發明人: 吳旻憲、謝佳訓、王宏銘、周文彬、邱子耕(核准日期: 2018/03/01 專利號碼: I616534 申請號: 105112116 專利期限: 2018/03/01-2036/02/28 專利權人: 長庚大學)
6. " 偵測周邊血液中 EGFR 基因突變腫瘤細胞之方法", 中華民國專利, 發明人: 謝佳訓、林鴻至、潘文明、吳旻憲、陳冠宇、王宏銘、林永昌、廖俊達、閻紫宸 (核准日期: 2021/11/11, 專利號碼: I745939 申請號: **109113267** 專利期限: **2021/11/11-2040/04/20** 專利權人: 長庚醫療財團法人林口長庚紀念醫院)
7. 利用光介電泳力及影像辨識方法進行血液循環腫瘤細胞純化分離 (Application of optically-induced-dielectrophoretic (ODEP) force and image analysis methods for the isolation and purification of blood circulating tumor cells (CTCs)) 細胞(2019 中華民國專利)I656344/中華民國

AWARD:

1. 2009 年台灣內科醫學會優良壁報獎
2. 2010 年林口長庚醫院優良教師
3. 2012 年台灣癌症聯合學術年會壁報論文, 佳作獎。
4. 2012 年第八屆國家新創獎 "Microfluidic Chip for High-Throughput Perfusion-Based Three-Dimensional Cell Culture"
5. 2013 年優良壁報獎. CellTech 2013 in San Diego U.S.A.
6. 2014 年台塑關係企業應用技術研討會研發創意實物獎學校組第二名
7. 2015 年優勝獎. (長庚 13th 屆台塑研討會)藉由微流體乳酸光感測裝置來進行循環腫瘤 癌細胞免標記偵測. 邱子耕、謝佳訓、吳旻憲.
8. 2015 國際智慧感測技術研討會暨第二十屆化學感測器協會研討會. 口頭論文競賽, 佳作獎。
9. 2015 國際智慧感測技術研討會暨第二十屆化學感測器協會研討會. 口頭論文競賽, 佳作獎。
10. 2016 年第二十一屆台灣癌症聯合學術年會. 壁報論文「臨床組」 優等。
11. 2017 年第十四屆國家新創獎. Innovation of Colon Cancer Screening Tissue papers.
12. 2018 年第二十三屆台灣癌症聯合學術年會 壁報論文 第二名

13. 2018 年第十五屆國家新創獎 “An optoelectronic microfluidic system for the high-purity isolation of rare cells.”
14. 2018 中華民國斐陶斐榮譽學會 榮譽會員
15. 2019 年第十六屆國家新創獎 “Toilet-Paper Type Fecal Occult Blood Test”
16. 2020 年第十七屆國家新創獎 “Toilet-Paper Type Fecal Occult Blood Test”
17. 2020 年台北生技獎 ”Technology Cooperation Award"
18. 2021 年 Taiwan Innotech Expo Invention Contest Gold Medal Award ”Methods for Screening Circulating Tumor Cells in Blood”台灣創新技術博覽會金牌獎 ”篩檢血液中循環腫瘤細胞之方法”

BOOK CHAPTER AUTHOR

- “The Negative Selection Strategy for Circulating Tumor Cells (CTCs) Isolation and Enumeration: Technical features, Methods and Clinical Applications.”. InTech - Tumor Metastasis. ISBN 978-953-51-2631-7, Print ISBN 978-953-51-2630-0, Published: September 14, 2016. DOI: [10.5772/64812](https://doi.org/10.5772/64812)
(<http://www.intechopen.com/books/tumor-metastasis/the-selection-strategy-for-circulating-tumor-cells-ctcs-isolation-and-enumeration-technical-features>)